

B2



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 277/00	A2	(11) International Publication Number: WO 00/51993 (43) International Publication Date: 8 September 2000 (08.09.00)
--	----	--

(21) International Application Number: PCT/US00/05195

(22) International Filing Date: 1 March 2000 (01.03.00)

(30) Priority Data:
60/122,718 3 March 1999 (03.03.99) US(71) Applicant: THE PROCTER & GAMBLE COMPANY
[US/US]; One Procter & Gamble Plaza, Cincinnati, OH 45202 (US).

(72) Inventors: CHENG, Menyan; 5860 Hazeltine Court, West Chester, OH 45069 (US). ALMSTEAD, Neil, Gregory; 6348 Trail Ridge Court, Loveland, OH 45140 (US). NATCHUS, Michael, George; 1096 Laurel Avenue, Glendale, OH 45246 (US). PIKUL, Stanislaw; 4640 Placepointe Drive, Mason, OH 45040 (US). DE, Biswanath; 11269 Cornell Woods Drive, Cincinnati, OH 45241 (US).


(74) Agents: REED, T., David et al.; The Procter & Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45217-1087 (US).

(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS



(57) Abstract

Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the compounds have a structure according to formula (I): where J, M, Q, T, W, X, Z, R¹, R², R³, R⁴, R^{4'}, R⁵, R⁶, R^{6'}, R⁷, m, and n have the meanings described in the specification. This invention also includes optical isomers, diastereomers and enantiomers of the formula above, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. Also disclosed are pharmaceutical compositions comprising these compounds, and methods of treating or preventing metalloprotease-related maladies using the compounds or the pharmaceutical compositions.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS

TECHNICAL FIELD

This invention is directed to compounds which are useful in treating diseases associated with metalloprotease activity, particularly zinc metalloprotease activity. The invention is also directed to pharmaceutical compositions comprising the compounds, and to methods of treating metalloprotease-related maladies using the compounds or the pharmaceutical compositions.

BACKGROUND

A number of structurally related metalloproteases effect the breakdown of structural proteins. These metalloproteases often act on the intercellular matrix, and thus are involved in tissue breakdown and remodeling. Such proteins are referred to as metalloproteases or MPs.

There are several different families of MPs, classified by sequence homology, disclosed in the art. These MPs include Matrix-Metallo Proteases (MMPs); zinc metalloproteases; many of the membrane bound metalloproteases; TNF converting enzymes; angiotensin-converting enzymes (ACEs); disintegrins, including ADAMs (see Wolfsberg et al, 131 J. Cell Bio. 275-78 October, 1995); and the enkephalinases. Examples of MPs include human skin fibroblast collagenase, human skin fibroblast gelatinase, human sputum collagenase, aggrecanase and gelatinase, and human stromelysin. Collagenases, stromelysin, aggrecanase and related enzymes are thought to be important in mediating the symptomatology of a number of diseases.

Potential therapeutic indications of MP inhibitors have been discussed in the literature. See, for example, U.S. Patents 5,506,242 (Ciba Geigy Corp.) and 5,403,952 (Merck & Co.); the following PCT published applications: WO 96/06074 (British Bio Tech Ltd.); WO 96/00214 (Ciba Geigy), WO 95/35275 (British Bio Tech Ltd.), WO 95/35276 (British Bio Tech Ltd.), WO 95/33731 (Hoffman-LaRoche), WO 95/33709 (Hoffman-LaRoche), WO 95/32944 (British Bio Tech Ltd.), WO 95/26989 (Merck), WO 95/29892 (DuPont Merck), WO 95/24921 (Inst. Ophthalmology), WO 95/23790 (SmithKline Beecham), WO 95/22966 (Sanofi Winthrop), WO 95/19965 (Glycomed), WO 95 19956 (British Bio Tech Ltd), WO 95/19957 (British Bio Tech Ltd.), WO 95/19961 (British Bio Tech Ltd.), WO 95/13289 (Chiroscience Ltd.), WO 95/12603

5 (Syntex), WO 95/09633 (Florida State Univ.), WO 95/09620 (Florida State Univ.), WO 95/04033 (Celltech), WO 94/25434 (Celltech), WO 94/25435 (Celltech); WO 93/14112 (Merck), WO 94/0019 (Glaxo), WO 93/21942 (British Bio Tech Ltd.), WO 92/22523 (Res. Corp. Tech Inc.), WO 94/10990 (British Bio Tech Ltd.), WO 93/09090 (Yamanouchi); British patents GB 2282598 (Merck) and GB 2268934 (British Bio Tech Ltd.); published European Patent Applications EP 10 95/684240 (Hoffman LaRoche), EP 574758 (Hoffman LaRoche) and EP 575844 (Hoffman LaRoche); published Japanese applications JP 08053403 (Fujusowa Pharm. Co. Ltd.) and JP 7304770 (Kanebo Ltd.); and Bird et al., *J. Med. Chem.*, vol. 37, pp. 158-69 (1994).

Examples of potential therapeutic uses of MP inhibitors include rheumatoid arthritis - Mullins, D. E., et al., *Biochim. Biophys. Acta.* (1983) 695:117-214; osteoarthritis - Henderson, 15 B., et al., *Drugs of the Future* (1990) 15:495-508; cancer - Yu, A. E. et al., *Matrix Metalloproteinases - Novel Targets for Directed Cancer Therapy*, *Drugs & Aging*, Vol. 11(3), p. 229-244 (Sept. 1997), Chambers, A.F. and Matrisian, L.M., *Review: Changing Views of the Role of Matrix Metalloproteinases in Metastasis*, *J. of the Nat'l Cancer Inst.*, Vol. 89(17), p. 1260-1270 (Sept. 1997), Bramhall, S.R., *The Matrix Metalloproteinases and Their Inhibitors in* 20 *Pancreatic Cancer*, *Internat'l J. of Pancreatology*, Vol. 4, p. 1101-1109 (May 1998), Nemunaitis, J. et al., *Combined Analysis of Studies of the Effects of the Matrix Metalloproteinase Inhibitor Marimastat on Serum Tumor Markers in Advanced Cancer: Selection of a Biologically Active and Tolerable Dose for Longer-term Studies*, *Clin. Cancer Res.*, Vol 4, p. 1101-1109 (May 1998), and Rasmussen, H.S. and McCann, P.P., *Matrix Metalloproteinase Inhibition as a Novel* 25 *Anticancer Strategy: A Review with Special Focus on Batimastat and Marimastat*, *Pharmacol. Ther.*, Vol 75(1), p. 69-75 (1997); the metastasis of tumor cells - *ibid*, Broadhurst, M. J., et al., European Patent Application 276,436 (published 1987), Reich, R., et al., *Cancer Res.*, Vol. 48, p. 3307-3312 (1988); multiple sclerosis - Gijbels et al., *J. Clin. Invest.*, vol. 94, p. 2177-2182 (1994); and various ulcerations or ulcerative conditions of tissue. For example, ulcerative 30 conditions can result in the cornea as the result of alkali burns or as a result of infection by *Pseudomonas aeruginosa*, *Acanthamoeba*, Herpes simplex and vaccinia viruses. Other examples of conditions characterized by undesired metalloprotease activity include periodontal disease, epidermolysis bullosa, fever, inflammation and scleritis (e.g., DeCicco et al., PCT published application WO 95/29892, published November 9, 1995).


35 In view of the involvement of such metalloproteases in a number of disease conditions, attempts have been made to prepare inhibitors to these enzymes. A number of such inhibitors are disclosed in the literature. Examples include U.S. Patent No. 5,183,900, issued February 2, 1993 to Galardy; U.S. Patent No. 4,996,358, issued February 26, 1991 to Handa et al.; U.S. Patent No. 4,771,038, issued September 13, 1988 to Wolanin et al.; U.S. Patent No. 4,743,587, issued May

10, 1988 to Dickens et al., European Patent Publication No. 575,844, published December 29, 1993 by Broadhurst et al.; International Patent Publication No. WO 93/09090, published May 13, 1993 by Isomura et al.; World Patent Publication 92/17460, published October 15, 1992 by Markwell et al.; and European Patent Publication No. 498,665, published August 12, 1992 by Beckett et al.

It would be advantageous to inhibit these metalloproteases in treating diseases related to unwanted metalloprotease activity. Though a variety of MP inhibitors have been prepared, there is a continuing need for potent matrix metalloprotease inhibitors useful in treating diseases associated with metalloprotease activity.

SUMMARY OF THE INVENTION

The invention provides compounds which are potent inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the present invention relates to compounds having a structure according to the following Formula (I):



where J, M, Q, T, W, X, Z, R¹, R², R³, R⁴, R^{4'}, R⁵, R⁶, R^{6'}, R⁷, *m*, and *n* have the meanings described in the Detailed Description section below. This invention also includes optical isomers, diastereomers and enantiomers of the formula above, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof.

The compounds of the present invention are useful for the treatment of diseases and conditions which are characterized by unwanted metalloprotease activity. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds. The invention still further provides methods of treatment for metalloprotease-related maladies.

DETAILED DESCRIPTION OF THE INVENTION

I. Terms and Definitions:

The following is a list of definitions for terms used herein:

5 The following is a list of definitions for terms used herein.

"Acyl" or "carbonyl" is a radical formed by removal of the hydroxy from a carboxylic acid (i.e., $R-C(=O)-$). Preferred acyl groups include (for example) acetyl, formyl, and propionyl.

"Alkyl" is a saturated hydrocarbon chain having 1 to 15 carbon atoms, preferably 1 to 10, more preferably 1 to 4 carbon atoms. "Alkene" is a hydrocarbon chain having at least one (preferably only one) carbon-carbon double bond and having 2 to 15 carbon atoms, preferably 2 to 10, more preferably 2 to 4 carbon atoms. "Alkyne" is a hydrocarbon chain having at least one (preferably only one) carbon-carbon triple bond and having 2 to 15 carbon atoms, preferably 2 to 10, more preferably 2 to 4 carbon atoms. Alkyl, alkene and alkyne chains (referred to collectively as "hydrocarbon chains") may be straight or branched and may be unsubstituted or substituted. Preferred branched alkyl, alkene and alkyne chains have one or two branches, preferably one branch. Preferred chains are alkyl. Alkyl, alkene and alkyne hydrocarbon chains each may be unsubstituted or substituted with from 1 to 4 substituents; when substituted, preferred chains are mono-, di-, or tri-substituted. Alkyl, alkene and alkyne hydrocarbon chains each may be substituted with halo, hydroxy, aryloxy (e.g., phenoxy), heteroaryloxy, acyloxy (e.g., acetoxy), carboxy, aryl (e.g., phenyl), heteroaryl, cycloalkyl, heterocycloalkyl, spirocycle, amino, amido, acylamino, keto, thioketo, cyano, or any combination thereof. Preferred hydrocarbon groups include methyl, ethyl, propyl, isopropyl, butyl, vinyl, allyl, butenyl, and exomethylenyl.

Also, as referred to herein, a "lower" alkyl, alkene or alkyne moiety (e.g., "lower alkyl") is a chain comprised of 1 to 6, preferably from 1 to 4, carbon atoms in the case of alkyl and 2 to 6, preferably 2 to 4, carbon atoms in the case of alkene and alkyne.

"Alkoxy" is an oxygen radical having a hydrocarbon chain substituent, where the hydrocarbon chain is an alkyl or alkenyl (i.e., -O-alkyl or -O-alkenyl). Preferred alkoxy groups include (for example) methoxy, ethoxy, propoxy and allyloxy.

30 "Aryl" is an aromatic hydrocarbon ring. Aryl rings are monocyclic or fused bicyclic ring systems. Monocyclic aryl rings contain 6 carbon atoms in the ring. Monocyclic aryl rings are also referred to as phenyl rings. Bicyclic aryl rings contain from 8 to 17 carbon atoms, preferably 9 to 12 carbon atoms, in the ring. Bicyclic aryl rings include ring systems wherein one ring is aryl and the other ring is aryl, cycloalkyl, or heterocycloalkyl. Preferred bicyclic aryl rings comprise 5-, 6- or 7-membered rings fused to 5-, 6-, or 7-membered rings. Aryl rings may be unsubstituted or substituted with from 1 to 4 substituents on the ring. Aryl may be substituted with halo, cyano, nitro, hydroxy, carboxy, amino, acylamino, alkyl, heteroalkyl, haloalkyl, phenyl, aryloxy, alkoxy, heteroalkyloxy, carbamyl, haloalkyl, methylenedioxy,

5 heteroaryloxy, or any combination thereof. Preferred aryl rings include naphthyl, tolyl, xylyl, and phenyl. The most preferred aryl ring radical is phenyl.

"Aryloxy" is an oxygen radical having an aryl substituent (i.e., -O-aryl). Preferred aryloxy groups include (for example) phenoxy, naphthyloxy, methoxyphenoxy, and methylenedioxyphenoxy.

10 "Cycloalkyl" is a saturated or unsaturated hydrocarbon ring. Cycloalkyl rings are not aromatic. Cycloalkyl rings are monocyclic, or are fused, spiro, or bridged bicyclic ring systems. Monocyclic cycloalkyl rings contain from about 3 to about 9 carbon atoms, preferably from 3 to 7 carbon atoms, in the ring. Bicyclic cycloalkyl rings contain from 7 to 17 carbon atoms, preferably from 7 to 12 carbon atoms, in the ring. Preferred bicyclic cycloalkyl rings comprise
15 4-, 5-, 6- or 7-membered rings fused to 5-, 6-, or 7-membered rings. Cycloalkyl rings may be unsubstituted or substituted with from 1 to 4 substituents on the ring. Cycloalkyl may be substituted with halo, cyano, alkyl, heteroalkyl, haloalkyl, phenyl, keto, hydroxy, carboxy, amino, acylamino, aryloxy, heteroaryloxy, or any combination thereof. Preferred cycloalkyl rings include cyclopropyl, cyclopentyl, and cyclohexyl.

20 "Halo" or "halogen" is fluoro, chloro, bromo or iodo. Preferred halo are fluoro, chloro and bromo; more preferred typically are chloro and fluoro, especially fluoro.


"Haloalkyl" is a straight, branched, or cyclic hydrocarbon substituted with one or more halo substituents. Preferred are C₁-C₁₂ haloalkyls; more preferred are C₁-C₆ haloalkyls; still more preferred still are C₁-C₃ haloalkyls. Preferred halo substituents are fluoro and chloro. The
25 most preferred haloalkyl is trifluoromethyl.

"Heteroatom" is a nitrogen, sulfur, or oxygen atom. Groups containing more than one heteroatom may contain different heteroatoms.


"Heteroalkyl" is a saturated or unsaturated chain containing carbon and at least one heteroatom, wherein no two heteroatoms are adjacent. Heteroalkyl chains contain from 2 to 15
30 member atoms (carbon and heteroatoms) in the chain, preferably 2 to 10, more preferably 2 to 5. For example, alkoxy (i.e., -O-alkyl or -O-heteroalkyl) radicals are included in heteroalkyl. Heteroalkyl chains may be straight or branched. Preferred branched heteroalkyl have one or two branches, preferably one branch. Preferred heteroalkyl are saturated. Unsaturated heteroalkyl have one or more carbon-carbon double bonds and/or one or more carbon-carbon triple bonds.
35 Preferred unsaturated heteroalkyls have one or two double bonds or one triple bond, more preferably one double bond. Heteroalkyl chains may be unsubstituted or substituted with from 1 to 4 substituents. Preferred substituted heteroalkyl are mono-, di-, or tri-substituted. Heteroalkyl may be substituted with lower alkyl, haloalkyl, halo, hydroxy, aryloxy,

- heteroaryloxy, acyloxy, carboxy, monocyclic aryl, heteroaryl, cycloalkyl, heterocycloalkyl, spirocycle, amino, acylamino, amido, keto, thioketo, cyano, or any combination thereof.


"Heteroaryl" is an aromatic ring containing carbon atoms and from 1 to about 6 heteroatoms in the ring. Heteroaryl rings are monocyclic or fused bicyclic ring systems. Monocyclic heteroaryl rings contain from about 5 to about 9 member atoms (carbon and heteroatoms), preferably 5 or 6 member atoms, in the ring. Bicyclic heteroaryl rings contain from 8 to 17 member atoms, preferably 8 to 12 member atoms, in the ring. Bicyclic heteroaryl rings include ring systems wherein one ring is heteroaryl and the other ring is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl. Preferred bicyclic heteroaryl ring systems comprise 5-, 6- or 7-membered rings fused to 5-, 6-, or 7-membered rings. Heteroaryl rings may be unsubstituted or substituted with from 1 to 4 substituents on the ring. Heteroaryl may be substituted with halo, cyano, nitro, hydroxy, carboxy, amino, acylamino, alkyl, heteroalkyl, haloalkyl, phenyl, alkoxy, aryloxy, heteroaryloxy, or any combination thereof. Preferred heteroaryl rings include, but are not limited to, the following:




-7-




Pyridine Pyridazine Pyrimidine Pyrazine 1,3,5-Triazine Indolizine Indole




Isoindole Benzofuran Benzothiophene 1H-Indazole Purine Quinoline



Benzimidazole Benzthiazole Benzoxazole Pteridine Carbazole



Isoquinoline Cinnoline Phthalazine Quinazoline Quinoxaline 1,8-Naphthypyridine



Acridine









Phenazine

“Heteroaryloxy” is an oxygen radical having a heteroaryl substituent (i.e., -O-heteroaryl). Preferred heteroaryloxy groups include (for example) pyridyloxy, furanyloxy, (thiophene)oxy, (oxazole)oxy, (thiazole)oxy, (isoxazole)oxy, pyrimidinyloxy, pyrazinyloxy, and benzothiazolyloxy.


“Heterocycloalkyl” is a saturated or unsaturated ring containing carbon atoms and from 1 to about 4 (preferably 1 to 3) heteroatoms in the ring. Heterocycloalkyl rings are not aromatic. Heterocycloalkyl rings are monocyclic, or are fused, bridged, or spiro bicyclic ring systems. Monocyclic heterocycloalkyl rings contain from about 3 to about 9 member atoms (carbon and heteroatoms), preferably from 5 to 7 member atoms, in the ring. Bicyclic heterocycloalkyl rings contain from 7 to 17 member atoms, preferably 7 to 12 member atoms, in the ring. Bicyclic heterocycloalkyl rings contain from about 7 to about 17 ring atoms, preferably from 7 to 12 ring atoms. Bicyclic heterocycloalkyl rings may be fused, spiro, or bridged ring systems. Preferred bicyclic heterocycloalkyl rings comprise 5-, 6- or 7-membered rings fused to 5-, 6-, or 7-membered rings. Heterocycloalkyl rings may be unsubstituted or substituted with from 1 to 4 substituents on the ring. Heterocycloalkyl may be substituted with halo, cyano, hydroxy, carboxy, keto, thioketo, amino, acylamino, acyl, amido, alkyl, heteroalkyl, haloalkyl, phenyl,

-8-


- 5 alkoxy, aryloxy or any combination thereof. Preferred substituents on heterocycloalkyl include halo and haloalkyl. Preferred heterocycloalkyl rings include, but are not limited to, the following:



-9-



2,3-Dihydro-1H-Isoindole Phthalan 1,4-Oxathiane 1,4-Dithiane hexahydro-Pyridazine



1,2-Benzisothiazoline Benzylsultam

As used herein, "mammalian metalloprotease" refers to the proteases disclosed in the "Background" section of this application. The compounds of the present invention are preferably active against "mammalian metalloproteases", including any metal-containing (preferably zinc-containing) enzyme found in animal, preferably mammalian, sources capable of catalyzing the breakdown of collagen, gelatin or proteoglycan under suitable assay conditions. Appropriate assay conditions can be found, for example, in U.S. Patent No. 4,743,587, which references the procedure of Cawston, et al., Anal. Biochem. (1979) 99:340-345; use of a synthetic substrate is described by Weingarten, H., et al., Biochem. Biophys. Res. Comm. (1984) 139:1184-1187. See also Knight, C.G. et al., "A Novel Coumarin-Labelled Peptide for Sensitive Continuous Assays of the Matrix Metalloproteases", FEBS Letters, Vol. 296, pp. 263-266 (1992). Any standard method for analyzing the breakdown of these structural proteins can, of course, be used. The present compounds are more preferably active against metalloprotease enzymes that are zinc-containing proteases which are similar in structure to, for example, human stromelysin or skin fibroblast collagenase. The ability of candidate compounds to inhibit metalloprotease activity can, of course, be tested in the assays described above. Isolated metalloprotease enzymes can be used to confirm the inhibiting activity of the invention compounds, or crude extracts which contain the range of enzymes capable of tissue breakdown can be used.

"Spirocycle" is an alkyl or heteroalkyl diradical substituent of alkyl or heteroalkyl wherein said diradical substituent is attached geminally and wherein said diradical substituent forms a ring, said ring containing 4 to 8 member atoms (carbon or heteroatom), preferably 5 or 6 member atoms.

While alkyl, heteroalkyl, cycloalkyl, and heterocycloalkyl groups may be substituted with hydroxy, amino, and amido groups as stated above, the following are not envisioned in the invention:

1. Enols (OH attached to a carbon bearing a double bond).

- 5 2. Amino groups attached to a carbon bearing a double bond (except for vinylogous amides).
3. More than one hydroxy, amino, or amido attached to a single carbon (except where two nitrogen atoms are attached to a single carbon atom and all three atoms are member atoms within a heterocycloalkyl ring).
- 10 4. Hydroxy, amino, or amido attached to a carbon that also has a heteroatom attached to it.
5. Hydroxy, amino, or amido attached to a carbon that also has a halogen attached to it.

A "pharmaceutically-acceptable salt" is a cationic salt formed at any acidic (e.g., hydroxamic or carboxylic acid) group, or an anionic salt formed at any basic (e.g., amino) group. Many such salts are known in the art, as described in World Patent Publication 15 87/05297, Johnston et al., published September 11, 1987 incorporated by reference herein. Preferred cationic salts include the alkali metal salts (such as sodium and potassium), and alkaline earth metal salts (such as magnesium and calcium) and organic salts. Preferred anionic salts include the halides (such as chloride salts), sulfonates, carboxylates, 20 phosphates, and the like.

Such salts are well understood by the skilled artisan, and the skilled artisan is able to prepare any number of salts given the knowledge in the art. Furthermore, it is recognized that the skilled artisan may prefer one salt over another for reasons of solubility, stability, formulation ease and the like. Determination and optimization of such salts is within the 25 purview of the skilled artisan's practice.

A "biohydrolyzable amide" is an amide of a hydroxamic acid-containing (i.e., R¹ in Formula (I) is -NHOH) metalloprotease inhibitor that does not interfere with the inhibitory activity of the compound, or that is readily converted *in vivo* by an animal, preferably a mammal, more preferably a human subject, to yield an active metalloprotease inhibitor. 30 Examples of such amide derivatives are alkoxyamides, where the hydroxyl hydrogen of the hydroxamic acid of Formula (I) is replaced by an alkyl moiety, and acyloxyamides, where the hydroxyl hydrogen is replaced by an acyl moiety (i.e., R-C(=O)-).

A "biohydrolyzable hydroxy imide" is an imide of a hydroxamic acid-containing metalloprotease inhibitor that does not interfere with the metalloprotease inhibitory activity of these compounds, or that is readily converted in vivo by an animal, preferably a mammal, more preferably a human subject to yield an active metalloprotease inhibitor. Examples of 35 such imide derivatives are those where the amino hydrogen of the hydroxamic acid of Formula (I) is replaced by an acyl moiety (i.e., R-C(=O)-).


A "biohydrolyzable ester" is an ester of a carboxylic acid-containing (i.e., R¹ in Formula (I) is -OH) metalloprotease inhibitor that does not interfere with the metalloprotease inhibitory activity of these compounds or that is readily converted by an animal to yield an active metalloprotease inhibitor. Such esters include lower alkyl esters, lower acyloxy-alkyl esters (such as acetoxymethyl, acetoxyethyl, aminocarbonyloxymethyl, pivaloyloxymethyl and pivaloyloxyethyl esters), lactonyl esters (such as phthalidyl and thiophthalidyl esters), lower alkoxyacyloxyalkyl esters (such as methoxycarbonyloxymethyl, ethoxycarbonyloxyethyl and isopropoxycarbonyloxyethyl esters), alkoxyalkyl esters, choline esters and alkyl acylamino alkyl esters (such as acetamidomethyl esters).

A "solvate" is a complex formed by the combination of a solute (e.g., a metalloprotease inhibitor) and a solvent (e.g., water). See J. Honig et al., The Van Nostrand Chemist's Dictionary, p. 650 (1953). Pharmaceutically-acceptable solvents used according to this invention include those that do not interfere with the biological activity of the metalloprotease inhibitor (e.g., water, ethanol, acetic acid, N,N-dimethylformamide and others known or readily determined by the skilled artisan).

The terms "optical isomer", "stereoisomer", and "diastereomer" have the standard art recognized meanings (see, e.g., Hawley's Condensed Chemical Dictionary, 11th Ed.). The illustration of specific protected forms and other derivatives of the compounds of the instant invention is not intended to be limiting. The application of other useful protecting groups, salt forms, etc. is within the ability of the skilled artisan.

II. Compounds:

The subject invention involves compounds having a structure according to Formula (I):



wherein

- (A) X is selected from -OH and -NHOH; or when J is -D-(CR¹⁴R^{14'})_nR¹⁵ where D is -O-, as defined below, X can optionally be a covalent bond which joins with J to form a 5 to 9 membered ring; (preferably X is -OH)

- 5 (B) W is selected from -S-, -O-, -N(R³²)-, -C(R³²)=C(R^{32'})-, -N=C(R³²)-, and -N=N- (preferably -S- or -C(R³²)=C(R^{32'})-), where R³² and R^{32'} each is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl (preferably hydrogen);
- 10 (C) R¹ is selected from hydrogen, hydroxyl, alkoxy, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, and halogen (preferably hydrogen or alkyl, more preferably hydrogen);
- 15 (D) R² is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, and heterocycloalkyl (preferably hydrogen or alkyl, more preferably hydrogen);
- (E) T is -(CR⁸R^{8'})_p-A-(CR^{8''}R^{8'''})_qR⁹ where
- (1) *p* is from 0 to about 4 (preferably 0 or 1);
 - (2) *q* is from 0 to about 4 (preferably 0 or 1);
 - (3) each R⁸, R^{8'}, R^{8''}, and R^{8'''} is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and haloalkyl (preferably hydrogen);
 - (4) R⁹ is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and halogen (preferably hydrogen, lower alkyl or aryl); and
 - (5) A is selected from a covalent bond; -O-; -SO_r- where *r* is 0, 1 or 2 (preferably 0 or 2); and -NR¹⁰- where R¹⁰ is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl (preferably lower alkyl), or R¹⁰ can join with R⁹ to form a ring with 5 to 8 members (preferably 5 or 6) and 1 to 3 heteroatoms (preferably 1 or 2); provided that when *p* is 0, A is a covalent bond;
- 20 (F) R³ is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and haloalkyl (preferably hydrogen or lower alkyl);
- (G) each R⁴ and R^{4'} is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, and alkoxy (preferably hydrogen); and *n* is from 0 to about 4 (preferably 0 or 1, more preferably 0);
- 35 (H) R⁵ is -(CR¹¹R^{11'})_nR¹² where

-13-

- 5 (1) s is from 0 to about 4 (preferably 0 or 1);
- (2) each R^{11} and $R^{11'}$ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and haloalkyl (preferably hydrogen); and
- 10 (3) R^{12} is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halogen, and GR^{13} where G is -O- or -S- and R^{13} is selected from hydrogen, alkyl, and aryl;
- (I) J is $-D-(CR^{14}R^{14'})_tR^{15}$ where
- (1) t is from 0 to about 4 (preferably 0 or 1);
- 15 (2) D is selected from -O-, $-SO_u-$ where u is from 0 to 2 (preferably 0 or 2); and $-NR^{16}-$ where R^{16} is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl (preferably lower alkyl), or R^{16} can join with R^{15} to form a ring with 5 to 8 members (preferably 5 or 6) and 1 to 3 heteroatoms (preferably 1 or 2);
- (3) each R^{14} and $R^{14'}$ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and haloalkyl (preferably hydrogen); and
- 20 (4) R^{15} is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl (preferably hydrogen, lower alkyl, aryl, and heteroaryl); or R^{15} can join with R^{13} to form an optionally substituted ring with 5 to 9 members of from 2 to 3 are heteroatoms;
- 25 (J) each R^6 and R^6 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, and alkoxy (preferably hydrogen); and m is from 0 to about 4 (preferably 0 or 1, more preferably 0);
- 30 (K) R^7 is $-(CR^{17}R^{17'})_vR^{18}$ where
- (1) v is from 0 to about 4 (preferably 0 or 1);
- (2) R^{17} and $R^{17'}$ are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and haloalkyl (preferably hydrogen); and
- 35 (3) R^{18} is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and halogen (preferably hydrogen or lower alkyl);

5 (L) M is $-E-(CR^{19}R^{19'})_wR^{20}$ where

- (1) w is from 0 to about 4 (preferably 0 or 1);
- (2) E is selected from a $-O-$; $-SO_x-$ where x is from 0 to 2 (preferably 0 or 2); and $-NR^{21}-$ where R^{21} is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl (preferably lower alkyl), or R^{21} can join with R^{20} to form a ring with 5 to 8 members (preferably 5 or 6) and 1 to 3 heteroatoms (preferably 1 or 2);
- (3) each R^{19} and $R^{19'}$ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and haloalkyl (preferably hydrogen); and
- 10 (4) R^{20} is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl (preferably lower alkyl, aryl or heteroaryl);

(M) Q is $-G'-(CR^{22}R^{22'})_yR^{23}$ where

- (1) y is from 0 to about 4 (preferably 0 or 1);
- 20 (2) G' is selected from a covalent bond; $-O-$; $-SO_z-$ where z is from 0 to 2 (preferably 0 or 2); and $-NR^{24}-$ where R^{24} is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl (preferably lower alkyl), or R^{24} can join with R^{22} to form a ring with 5 to 8 members (preferably 5 or 6) and 1 to 3 heteroatoms (preferably 1 or 2);
- 25 (3) each R^{22} and $R^{22'}$ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and haloalkyl (preferably hydrogen); and
- (4) R^{23} is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl (preferably hydrogen, lower alkyl, aryl or heteroaryl), or R^{23} can join with R^{20} to form a ring having from 5 to 8 members (preferably 5 or 6) with 1 to 3 heteroatoms (preferably 1 or 2); and

(N) Z is selected from


- 35 (1) cycloalkyl and heterocycloalkyl;
- (2) $-D'-(CR^{25}R^{25'})_aR^{26}$ where
- (a) a is from 0 to about 4 (preferably 0 or 1);

- (b) when a is from 0 to about 4 then D' is selected from $-C\equiv C-$, $-CH=CH-$, $-O-$, and $-S-$, and when a is from 1 to about 4, then D is selected from $-C\equiv C-$, $-CH=CH-$, $-N=N-$, $-O-$, $-S-$ and $-SO_2-$ (preferably $-C\equiv C-$, $-CH=CH-$, $-O-$ or $-S-$);
- (c) each R^{25} and $R^{25'}$ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, and alkoxy (preferably hydrogen or lower alkyl); and
- (d) R^{26} is selected from hydrogen, aryl, heteroaryl, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, heterocycloalkyl and cycloalkyl (preferably aryl, heteroaryl, heterocycloalkyl or cycloalkyl); and, if D' is $-C\equiv C-$ or $-CH=CH-$, then R^{26} may also be selected from $-CONR^{27}R^{27'}$ where (i) R^{27} and $R^{27'}$ are independently selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, or (ii) R^{27} and $R^{27'}$, together with the nitrogen atom to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 (preferably 5 or 6) ring atoms of which from 1 to 3 (preferably 1 or 2) are heteroatoms;
- (3) $-NR^{28}R^{28'}$ where
- (a) R^{28} and $R^{28'}$ each is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heteroalkyl (preferably hydrogen, alkyl or aryl) and $-C(O)-Q'-(CR^{29}R^{29'})_bR^{30}$ where
- (i) b is from 0 to about 4 (preferably 0 or 1);
- (ii) Q' is selected from a covalent bond and $-NR^{31}-$ (preferably a covalent bond); and
- (iii) each R^{29} and $R^{29'}$ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, and alkoxy (preferably hydrogen or lower alkyl); R^{30} and R^{31} (i) each is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, or (ii) R^{30} and R^{31} , together with the atoms to which they are bonded, join to form an optionally substituted

-16-

heterocyclic ring containing from 5 to 8 (preferably 5 or 6) ring atoms of which from 1 to 3 (preferably 1 or 2) are heteroatoms (preferably R^{30} is alkyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl); or R^{28} and R^{31} , together with the nitrogen atoms to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 ring atoms of which from 2 to 3 are heteroatoms; or

- (b) R^{28} and $R^{28'}$, together with the nitrogen atom to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 (preferably 5 or 6) ring atoms of which from 1 to 3 (preferably 1 or 2) are heteroatoms; and



- (a) E' and Y are independently selected from $-CH-$ and $-N-$;
- (b) L is selected from $-S-$, $-O-$, $-N(R^{35})-$, $-C(R^{35})=C(R^{35'})-$, $N=C(R^{35})-$, and $-N=N-$ [preferably $-N=C(R^{35})-$ or $C(R^{35})=C(R^{35'})-$], where R^{35} and $R^{35'}$ each is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl (preferably hydrogen or lower alkyl);
- (c) c is from 0 to about 4 (preferably 0 or 1);
- (d) each R^{33} and $R^{33'}$ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, and alkoxy (preferably hydrogen or lower alkyl);
- (e) A' is selected from a covalent bond, $-O-$, $-SO_d-$, $-C(O)-$, $C(O)NR^{36}-$, $-NR^{36}-$, and $-NR^{36}C(O)-$ [preferably $-O-$, $-S-$, SO_2- , $C(O)NR^{36}-$, $-NR^{36}-$, and $-NR^{36}C(O)-$; more preferably $-O-$]; where d is from 0 to 2 and R^{36} is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, haloalkyl (preferably lower alkyl or aryl); and
- (f) T' is $-(CR^{37}R^{37'})_e-R^{38}$ where e is from 0 to about 4 (preferably 0 or 1); each R^{37} and $R^{37'}$ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl,


heterocycloalkyl, halogen, haloalkyl, hydroxy, alkoxy and aryloxy (preferably hydrogen or lower alkyl); and R^{38} is selected from hydrogen, alkyl, alkenyl, alkynyl, halogen, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl (preferably lower alkyl or aryl); or R^{36} and R^{38} , together with the atoms to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 (preferably 5 or 6) atoms of which 1 to 3 (preferably 1 or 2) are heteroatoms; or R^{35} and R^{38} , together with the atoms to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 (preferably 5 or 6) atoms of which 1 to 3 (preferably 1 or 2) are heteroatoms;

or an optical isomer, diastereomer or enantiomer for Formula (I), or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof.

III. Compound Preparation:

The compounds of the invention can be prepared using a variety of procedures. The starting materials used in preparing the compounds of the invention are known, made by known methods, or are commercially available. Particularly preferred syntheses are described in the following general reaction schemes. (The R groups used to illustrate the reaction schemes do not necessarily correlate to the respective R groups used to describe the various aspects of the Formula I compounds. That is, for example, R^1 in Formula (I) does not represent the same moiety as R_1 here.) Specific examples for making the compounds of the present invention are set forth in Section VIII, below.

Scheme 1




In Scheme 1, the acetate S1a depicted as starting material can be prepared from commercially available sources and converted to the corresponding allyl derivative such as S1b as described in *Tetrahedron Lett.* 1994, 35 (22), 3669.

Further functionalization of the alkene can be accomplished using methods well known to the skilled artisan. Such a process can be used to access a wide range of functionalities including but not limited to the epoxide S1d depicted in Scheme 1. Some form of nucleophilic addition to the epoxide ring can then occur, using well known methodology to produce the lactone S1e.


If desired, the ester functionality in compounds of type S1e can be transesterified, saponified to an acid or treated with basic hydroxyl amine to give the hydroxamic acid.

Scheme 2



In Scheme 2, the allyl glycine S2a is converted to the aldehyde S2d using known methodology (Kurokawa et al, *Tetrahedron*, 1993, 49, 6195.). The aldehyde can then be transformed using known protecting group methods to the corresponding acetal, aminal, or thioacetal S2e. The amine protecting group can then be removed and the sulfonamide group can be added. The lactone can then be transformed to the desired carboxylic acid S2g.

Scheme 3




Nucleophilic additions of the anion generated from amino acid condensate S3a to various electrophiles are a well known method for generating amino acids of type S3c in an asymmetric way (Myers et al, *J. Am. Chem. Soc.* 1997, 119, 656.). These can then be functionalized

-19-

5 according to known methods and carried forward as described above to generate a variety of compounds which fall within the scope of this invention.

Scheme 4



10 The oxazolidinone S4a can be transformed to the aluminum enolate which can then react with the corresponding epoxide S4b to produce the alcohol S4c using known methodology (Smith et al, *J. Am. Chem. Soc.* 1995, 117, 11113.). The alcohol S4c can then be further elaborated to amino acid S4d using well described techniques. Final elaboration of the compound to produce S4e can occur in a manner analogous to that described above in Scheme 1.

15 A variety of compounds can be generated in a similar fashion, using the guidance of the schemes above.

It is recognized that it is preferable to use a protecting group for any reactive functionality such as a carboxyl, hydroxyl and the like, during the formation of the sultamester. This is standard practice, well within the normal practice of the skilled artisan.

20 In the above scheme, where R is alkoxy or alkylthio, the corresponding hydroxy or thiol compounds are derived from the final compounds by using a standard dealkylating procedure (Bhatt, et al., "Cleavage of Ethers", *Synthesis*, 1983, pp. 249-281).

These steps may be varied to increase yield of desired product. The skilled artisan will recognize the judicious choice of reactants, solvents, and temperatures is an important component in any successful synthesis. Determination of optimal conditions, etc. is routine. Thus the skilled artisan can make a variety of compounds using the guidance of the schemes above.

It is recognized that the skilled artisan in the art of organic chemistry can readily carry out standard manipulations of organic compounds without further direction; that is, it is well within the scope and practice of the skilled artisan to carry out such manipulations. These

5 include, but are not limited to, reduction of carbonyl compounds to their corresponding alcohols, oxidations of hydroxyls and the like, acylations, aromatic substitutions, both electrophilic and nucleophilic, etherifications, esterification and saponification and the like. Examples of these manipulations are discussed in standard texts such as March, Advanced Organic Chemistry (Wiley), Carey and Sundberg, Advanced Organic Chemistry (Vol. 2) and other art that the skilled
10 artisan is aware of.

The skilled artisan will also readily appreciate that certain reactions are best carried out when another potentially reactive functionality on the molecule is masked or protected, thus avoiding any undesirable side reactions and/or increasing the yield of the reaction. Often the skilled artisan utilizes protecting groups to accomplish such increased yields or to avoid the
15 undesired reactions. These reactions are found in the literature and are also well within the scope of the skilled artisan. Examples of many of these manipulations can be found for example in T. Greene, Protecting Groups in Organic Synthesis. Of course, amino acids used as starting materials with reactive side chains are preferably blocked to prevent undesired side reactions.

The compounds of the invention may have one or more chiral centers. As a result, one
20 may selectively prepare one optical isomer, including diastereomer and enantiomer, over another, for example by chiral starting materials, catalysts or solvents, or may prepare both stereoisomers or both optical isomers, including diastereomers and enantiomers at once (a racemic mixture). Since the compounds of the invention may exist as racemic mixtures, mixtures of optical isomers, including diastereomers and enantiomers, or stereoisomers may be separated using
25 known methods, such as chiral salts, chiral chromatography and the like.

In addition, it is recognized that one optical isomer, including diastereomer and enantiomer, or stereoisomer may have favorable properties over the other. Thus when disclosing and claiming the invention, when one racemic mixture is disclosed, it is clearly contemplated that both optical isomers, including diastereomers and enantiomers, or stereoisomers substantially
30 free of the other are disclosed and claimed as well.

5 IV. Methods of use:

10 Metalloproteases (MPs) found in the body operate, in part, by breaking down the extracellular matrix, which comprises extracellular proteins and glycoproteins. Inhibitors of metalloproteases are useful in treating diseases caused, at least in part, by the breakdown of such proteins and glycoproteins. These proteins and glycoproteins play an important role in maintaining the size, shape, structure and stability of tissue in the body. Thus, MPs are intimately involved in tissue remodeling.

15 As a result of this activity, MPs have been said to be active in many disorders involving either the: (1) breakdown of tissues including opthalmic diseases; degenerative diseases, such as arthritis, multiple sclerosis and the like; and metastasis or mobility of tissues in the body; or (2) remodeling of tissues including cardiac disease, fibrotic disease, scarring, benign hyperplasia, and the like.

The compounds of the present invention prevent or treat disorders, diseases and/or unwanted conditions which are characterized by unwanted or elevated activity by MPs. For example, the compounds can be used to inhibit MPs which:

- 20 1. destroy structural proteins (i.e. the proteins that maintain tissue stability and structure);
2. interfere in inter/intracellular signaling, including those implicated in cytokine up-regulation, and/or cytokine processing and/or inflammation, tissue degradation and other maladies [Mohler KM, et al, Nature 370 (1994) 218-220, Gearing AJH, et al, Nature 370 (1994) 555-557 McGeehan GM, et al, Nature 370 (1994) 558-561]; and
- 25 3. facilitate processes which are undesired in the subject being treated, for example, the processes of sperm maturation, egg fertilization and the like.

30 As used herein, an "MP related disorder" or "MP related disease" is one that involves unwanted or elevated MP activity in the biological manifestation of the disease or disorder; in the biological cascade leading to the disorder; or as a symptom of the disorder. This "involvement" of the MP includes:

1. The unwanted or elevated MP activity as a "cause" of the disorder or biological manifestation, whether the activity is elevated genetically, by infection, by autoimmunity, trauma, biomechanical causes, lifestyle [e.g. obesity] or by some other cause;
- 35 2. The MP as part of the observable manifestation of the disease or disorder. That is, the disease or disorder is measurable in terms of the increased MP activity. From a clinical standpoint, unwanted or elevated MP levels indicate the disease, however, MPs need not be the "hallmark" of the disease or disorder; or

-22-

- 5 3. The unwanted or elevated MP activity is part of the biochemical or cellular cascade that results or relates to the disease or disorder. In this respect, inhibition of the MP activity interrupts the cascade, and thus controls the disease.

The term "treatment" is used herein to mean that, at a minimum, administration of a compound of the present invention mitigates a disease associated with unwanted or elevated MP activity in a mammalian subject, preferably in humans. Thus, the term "treatment" includes: preventing an MP-mediated disease from occurring in a mammal, particularly when the mammal is predisposed to acquiring the disease, but has not yet been diagnosed with the disease; inhibiting the MP-mediated disease; and/or alleviating or reversing the MP-mediated disease. Insofar as the methods of the present invention are directed to preventing disease states associated with unwanted MP activity, it is understood that the term "prevent" does not require that the disease state be completely thwarted. (See Webster's Ninth Collegiate Dictionary.) Rather, as used herein, the term preventing refers to the ability of the skilled artisan to identify a population that is susceptible to MP-related disorders, such that administration of the compounds of the present invention may occur prior to onset of the disease. The term does not imply that the disease state be completely avoided. For example, osteoarthritis (OA) is the most common rheumatological disease with some joint changes radiologically detectable in 80% of people over 55 years of age. Fife, R.S., "A Short History of Osteoarthritis", Osteoarthritis: Diagnosis and Medical/Surgical Management, R.W. Moskowitz, D.S. Howell, V.M. Goldberg and H.J. Mankin Eds., p 11-14 (1992). A common risk factor that increases the incidence of OA is traumatic injury of the joint. Surgical removal of the meniscus following knee injury increases the risk of radiographically detectable OA and this risk increases with time. Roos, H et al. "Knee Osteoarthritis After Meniscectomy: Prevalence of Radiographic Changes After Twenty-one Years, Compared with Matched Controls." Arthritis Rheum., Vol. 41, pp 687-693; Roos, H et al. "Osteoarthritis of the Knee After Injury to the Anterior Cruciate Ligament or Meniscus: The Influence of Time and Age." Osteoarthritis Cartilage., Vol. 3, pp 261-267 (1995). Thus, this patient population is identifiable and could receive administration of a compound of the present invention before progression of the disease. Thus, progression of OA in such individuals would be "prevented".

Advantageously, many MPs are not distributed evenly throughout the body. Thus, the distribution of MPs expressed in various tissues are often specific to those tissues. For example, the distribution of metalloproteases implicated in the breakdown of tissues in the joints is not the same as the distribution of metalloproteases found in other tissues. Though not essential for activity or efficacy, certain diseases, disorders, and unwanted conditions preferably are treated

5 with compounds that act on specific MPs found in the affected tissues or regions of the body. For example, a compound which displays a higher degree of affinity and inhibition for an MP found in the joints (e.g. chondrocytes) would be preferred for treatment of a disease, disorder, or unwanted condition found there than other compounds which are less specific.

In addition, certain inhibitors are more bioavailable to certain tissues than others.
10 Choosing an MP inhibitor which is more bioavailable to a certain tissue and which acts on the specific MPs found in that tissue, provides for specific treatment of the disease, disorder, or unwanted condition. For example, compounds of this invention vary in their ability to penetrate into the central nervous system. Thus, compounds may be selected to produce effects mediated through MPs found specifically outside the central nervous system.

15 Determination of the specificity of an inhibitor of a specific MP is within the skill of the artisan in that field. Appropriate assay conditions can be found in the literature. Specifically, assays are known for stromelysin and collagenase. For example, U.S. Pat. No. 4,743,587 references the procedure of Cawston, et al., Anal Biochem (1979) 99:340-345. See also, Knight, C.G. et al., "A Novel Coumarin-Labelled Peptide for Sensitive Continuous Assays of the Matrix
20 Metalloproteases", FEBS Letters, Vol. 296, pp. 263-266 (1992). The use of a synthetic substrate in an assay is described by Weingarten, H., et al., Biochem Biophys Res Comm (1984) 139:1184-1187. Any standard method for analyzing the breakdown of structural proteins by MPs can, of course, be used. The ability of compounds of the invention to inhibit metalloprotease activity can, of course, be tested in the assays found in the literature, or variations thereof. Isolated
25 metalloprotease enzymes can be used to confirm the inhibiting activity of the invention compounds, or crude extracts which contain the range of enzymes capable of tissue breakdown can be used.

The compounds of this invention are also useful for prophylactic or acute treatment. They are administered in any way the skilled artisan in the fields of medicine or pharmacology
30 would desire. It is immediately apparent to the skilled artisan that preferred routes of administration will depend upon the disease state being treated and the dosage form chosen. Preferred routes for systemic administration include administration perorally or parenterally.

However, the skilled artisan will readily appreciate the advantage of administering the MP inhibitor directly to the affected area for many diseases, disorders, or unwanted conditions.
35 For example, it may be advantageous to administer MP inhibitors directly to the area of the disease, disorder, or unwanted condition such as in the area affected by surgical trauma (e. g., angioplasty), scarring, burning (e.g., topical to the skin), or for ophthalmic and periodontal indications.

5 Because the remodeling of bone involves MPs, the compounds of the invention are useful in preventing prosthesis loosening. It is known in the art that over time prostheses loosen, become painful, and may result in further bone injury, thus demanding replacement. The need for replacement of such prostheses includes those such as in, joint replacements (for example hip, knee and shoulder replacements), dental prosthesis, including dentures, bridges and prosthesis
10 secured to the maxilla and/or mandible.

 MPs are also active in remodeling of the cardiovascular system (for example, in congestive heart failure). It has been suggested that one of the reasons angioplasty has a higher than expected long term failure rate (reclosure over time) is that MP activity is not desired or is elevated in response to what may be recognized by the body as "injury" to the basement
15 membrane of the vessel. Thus regulation of MP activity in indications such as dilated cardiomyopathy, congestive heart failure, atherosclerosis, plaque rupture, reperfusion injury, ischemia, chronic obstructive pulmonary disease, angioplasty restenosis and aortic aneurysm may increase long term success of any other treatment, or may be a treatment in itself.

 In skin care, MPs are implicated in the remodeling or "turnover" of skin. As a result, the
20 regulation of MPs improves treatment of skin conditions including but not limited to, wrinkle repair, regulation and prevention and repair of ultraviolet induced skin damage. Such a treatment includes prophylactic treatment or treatment before the physiological manifestations are obvious. For example, the MP may be applied as a pre-exposure treatment to prevent ultraviolet damage and/or during or after exposure to prevent or minimize post-exposure damage. In addition, MPs
25 are implicated in skin disorders and diseases related to abnormal tissues that result from abnormal turnover, which includes metalloprotease activity, such as epidermolysis bullosa, psoriasis, scleroderma and atopic dermatitis. The compounds of the invention are also useful for treating the consequences of "normal" injury to the skin including scarring or "contraction" of tissue, for example, following burns. MP inhibition is also useful in surgical procedures
30 involving the skin for prevention of scarring, and promotion of normal tissue growth including in such applications as limb reattachment and refractory surgery (whether by laser or incision).

 In addition, MPs are related to disorders involving irregular remodeling of other tissues, such as bone, for example, in otosclerosis and/or osteoporosis, or for specific organs, such as in liver cirrhosis and fibrotic lung disease. Similarly in diseases such as multiple sclerosis, MPs
35 may be involved in the irregular modeling of blood brain barrier and/or myelin sheaths of nervous tissue. Thus regulating MP activity may be used as a strategy in treating, preventing, and controlling such diseases.

 MPs are also thought to be involved in many infections, including cytomegalovirus [CMV]; retinitis; HIV, and the resulting syndrome, AIDS.

5 MPs may also be involved in extra vascularization where surrounding tissue needs to be broken down to allow new blood vessels such as in angiofibroma and hemangioma.

 Since MPs break down the extracellular matrix, it is contemplated that inhibitors of these enzymes can be used as birth control agents, for example in preventing ovulation, in preventing penetration of the sperm into and through the extracellular milieu of the ovum, implantation of
10 the fertilized ovum and in preventing sperm maturation.

 In addition they are also contemplated to be useful in preventing or stopping premature labor and delivery.

 Since MPs are implicated in the inflammatory response and in the processing of cytokines, the compounds are also useful as anti-inflammatories, for use in disease where
15 inflammation is prevalent including, inflammatory bowel disease, Crohn's disease, ulcerative colitis, pancreatitis, diverticulitis, asthma or related lung disease, rheumatoid arthritis, gout and Reiter's Syndrome.

 Where autoimmunity is the cause of the disorder, the immune response often triggers MP and cytokine activity. Regulation of MPs in treating such autoimmune disorders is a useful
20 treatment strategy. Thus MP inhibitors can be used for treating disorders including, lupus erythmatosis, ankylosing spondylitis, and autoimmune keratitis. Sometimes the side effects of autoimmune therapy result in exacerbation of other conditions mediated by MPs, here MP inhibitor therapy is effective as well, for example, in autoimmune-therapy-induced fibrosis.

 In addition, other fibrotic diseases lend themselves to this type of therapy, including
25 pulmonary disease, bronchitis, emphysema, cystic fibrosis, acute respiratory distress syndrome (especially the acute phase response).

 Where MPs are implicated in the undesired breakdown of tissue by exogenous agents, these can be treated with MP inhibitors. For example, they are effective as rattle snake bite antidote, as anti-vessicants, in treating allergic inflammation, septicemia and shock. In addition,
30 they are useful as antiparasitics (e.g., in malaria) and antiinfectives. For example, they are thought to be useful in treating or preventing viral infection, including infection which would result in herpes, "cold" (e.g., rhinoviral infection), meningitis, hepatitis, HIV infection and AIDS.

 MP inhibitors are also thought to be useful in treating Alzheimer's disease, amyotrophic
35 lateral sclerosis (ALS), muscular dystrophy, complications resulting from or arising out of diabetes, especially those involving loss of tissue viability, coagulation, Graft vs. Host disease, leukemia, cachexia, anorexia, proteinuria, and perhaps regulation of hair growth.

 For some diseases, conditions or disorders MP inhibition is contemplated to be a preferred method of treatment. Such diseases, conditions or disorders include, arthritis

-26-

5 (including osteoarthritis and rheumatoid arthritis), cancer (especially the prevention or arrest of tumor growth and metastasis), ocular disorders (especially corneal ulceration, lack of corneal healing, macular degeneration, and pterygium), and gum disease (especially periodontal disease, and gingivitis)

10 Compounds preferred for, but not limited to, the treatment of arthritis (including osteoarthritis and rheumatoid arthritis) are those compounds that are selective for the matrix metalloproteases and the disintegrin metalloproteases.

Compounds preferred for, but not limited to, the treatment of cancer (especially the prevention or arrest of tumor growth and metastasis) are those compounds that preferentially inhibit gelatinases or type IV collagenases.

15 Compounds preferred for, but not limited to, the treatment of ocular disorders (especially corneal ulceration, lack of corneal healing, macular degeneration, and pterygium) are those compounds that broadly inhibit metalloproteases. Preferably these compounds are administered topically, more preferably as a drop or gel.

20 Compounds preferred for, but not limited to, the treatment of gum disease (especially periodontal disease, and gingivitis) are those compounds that preferentially inhibit collagenases.

V. Compositions:

The compositions of the invention comprise:

- (a) a safe and effective amount of a compound of the invention; and
- (b) a pharmaceutically-acceptable carrier.

25 As discussed above, numerous diseases are known to be mediated by excess or undesired metalloprotease activity. These include tumor metastasis, osteoarthritis, rheumatoid arthritis, skin inflammation, ulcerations, particularly of the cornea, reaction to infection, periodontitis and the like. Thus, the compounds of the invention are useful in therapy with regard to conditions involving this unwanted activity.

30 The invention compounds can therefore be formulated into pharmaceutical compositions for use in treatment or prophylaxis of these conditions. Standard pharmaceutical formulation techniques are used, such as those disclosed in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., latest edition.

35 A "safe and effective amount" of a Formula (I) compound is an amount that is effective, to inhibit metalloproteases at the site(s) of activity, in an animal, preferably a mammal, more preferably a human subject, without undue adverse side effects (such as toxicity, irritation, or allergic response), commensurate with a reasonable benefit/risk ratio when used in the manner of this invention. The specific "safe and effective amount" will,

5 obviously, vary with such factors as the particular condition being treated, the physical condition of the patient, the duration of treatment, the nature of concurrent therapy (if any), the specific dosage form to be used, the carrier employed, the solubility of the Formula (I) compound therein, and the dosage regimen desired for the composition.

10 In addition to the subject compound, the compositions of the subject invention contain a pharmaceutically-acceptable carrier. The term "pharmaceutically-acceptable carrier", as used herein, means one or more compatible solid or liquid filler diluents or encapsulating substances which are suitable for administration to an animal, preferably a mammal, more preferably a human. The term "compatible", as used herein, means that the components of the composition are capable of being commingled with the subject compound, and with each other, in a manner
15 such that there is no interaction which would substantially reduce the pharmaceutical efficacy of the composition under ordinary use situations. Pharmaceutically-acceptable carriers must, of course, be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the animal, preferably a mammal, more preferably a human being treated.

Some examples of substances which can serve as pharmaceutically-acceptable carriers or
20 components thereof are sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; powdered tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols such as propylene
25 glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; alginic acid; emulsifiers, such as the Tweens®; wetting agents, such sodium lauryl sulfate; coloring agents; flavoring agents; tableting agents, stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline; and phosphate buffer solutions.

The choice of a pharmaceutically-acceptable carrier to be used in conjunction with the
30 subject compound is basically determined by the way the compound is to be administered.

If the subject compound is to be injected, the preferred pharmaceutically-acceptable carrier is sterile, physiological saline, with blood-compatible suspending agent, the pH of which has been adjusted to about 7.4.

In particular, pharmaceutically-acceptable carriers for systemic administration
35 include sugars, starches, cellulose and its derivatives, malt, gelatin, talc, calcium sulfate, vegetable oils, synthetic oils, polyols, alginic acid, phosphate buffer solutions, emulsifiers, isotonic saline, and pyrogen-free water. Preferred carriers for parenteral administration include propylene glycol, ethyl oleate, pyrrolidone, ethanol, and sesame oil. Preferably, the

5 pharmaceutically-acceptable carrier, in compositions for parenteral administration, comprises at least about 90% by weight of the total composition.

The compositions of this invention are preferably provided in unit dosage form. As used herein, a "unit dosage form" is a composition of this invention containing an amount of a Formula (I) compound that is suitable for administration to an animal, preferably a
10 mammal, more preferably a human subject, in a single dose, according to good medical practice. These compositions preferably contain from about 5 mg (milligrams) to about 1000 mg, more preferably from about 10 mg to about 500 mg, more preferably from about 10 mg to about 300 mg, of a Formula (I) compound.

The compositions of this invention may be in any of a variety of forms, suitable (for
15 example) for oral, rectal, topical, nasal, ocular or parenteral administration. Depending upon the particular route of administration desired, a variety of pharmaceutically-acceptable carriers well-known in the art may be used. These include solid or liquid fillers, diluents, hydrotropes, surface-active agents, and encapsulating substances. Optional pharmaceutically-active materials may be included, which do not substantially interfere with
20 the inhibitory activity of the Formula (I) compound. The amount of carrier employed in conjunction with the Formula (I) compound is sufficient to provide a practical quantity of material for administration per unit dose of the Formula (I) compound. Techniques and compositions for making dosage forms useful in the methods of this invention are described in the following references, all incorporated by reference herein: Modern Pharmaceutics,
25 Chapters 9 and 10 (Banker & Rhodes, editors, 1979); Lieberman et al., Pharmaceutical Dosage Forms: Tablets (1981); and Ansel, Introduction to Pharmaceutical Dosage Forms 2d Edition (1976).

Various oral dosage forms can be used, including such solid forms as tablets, capsules, granules and bulk powders. These oral forms comprise a safe and effective
30 amount, usually at least about 5%, and preferably from about 25% to about 50%, of the Formula (I) compound. Tablets can be compressed, tablet triturates, enteric-coated, sugar-coated, film-coated, or multiple-compressed, containing suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents. Liquid oral dosage forms include aqueous solutions, emulsions,
35 suspensions, solutions and/or suspensions reconstituted from non-effervescent granules, and effervescent preparations reconstituted from effervescent granules, containing suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, melting agents, coloring agents and flavoring agents.

5 The pharmaceutically-acceptable carrier suitable for the preparation of unit dosage forms for peroral administration are well-known in the art. Tablets typically comprise conventional pharmaceutically-compatible adjuvants as inert diluents, such as calcium carbonate, sodium carbonate, mannitol, lactose and cellulose; binders such as starch, gelatin and sucrose; disintegrants such as starch, alginic acid and croscarmellose; lubricants such as magnesium
10 stearate, stearic acid and talc. Glidants such as silicon dioxide can be used to improve flow characteristics of the powder mixture. Coloring agents, such as the FD&C dyes, can be added for appearance. Sweeteners and flavoring agents, such as aspartame, saccharin, menthol, peppermint, and fruit flavors, are useful adjuvants for chewable tablets. Capsules typically comprise one or more solid diluents disclosed above. The selection of carrier components
15 depends on secondary considerations like taste, cost, and shelf stability, which are not critical for the purposes of the subject invention, and can be readily made by a person skilled in the art.

 Peroral compositions also include liquid solutions, emulsions, suspensions, and the like. The pharmaceutically-acceptable carriers suitable for preparation of such compositions are well known in the art. Typical components of carriers for syrups, elixirs, emulsions and suspensions
20 include ethanol, glycerol, propylene glycol, polyethylene glycol, liquid sucrose, sorbitol and water. For a suspension, typical suspending agents include methyl cellulose, sodium carboxymethyl cellulose, Avicel[®] RC-591, tragacanth and sodium alginate; typical wetting agents include lecithin and polysorbate 80; and typical preservatives include methyl paraben and sodium benzoate. Peroral liquid compositions may also contain one or more components such as
25 sweeteners, flavoring agents and colorants disclosed above.

 Such compositions may also be coated by conventional methods, typically with pH or time-dependent coatings, such that the subject compound is released in the gastrointestinal tract in the vicinity of the desired topical application, or at various times to extend the desired action. Such dosage forms typically include, but are not limited to, one or more of cellulose acetate
30 phthalate, polyvinylacetate phthalate, hydroxypropyl methyl cellulose phthalate, ethyl cellulose, Eudragit[®] coatings, waxes and shellac.

 Compositions of the subject invention may optionally include other drug actives.

 Other compositions useful for attaining systemic delivery of the subject compounds include sublingual, buccal and nasal dosage forms. Such compositions typically comprise one or
35 more of soluble filler substances such as sucrose, sorbitol and mannitol; and binders such as acacia, microcrystalline cellulose, carboxymethyl cellulose and hydroxypropyl methyl cellulose. Glidants, lubricants, sweeteners, colorants, antioxidants and flavoring agents disclosed above may also be included.

5 The compositions of this invention can also be administered topically to a subject, e.g., by the direct laying on or spreading of the composition on the epidermal or epithelial tissue of the subject, or transdermally via a "patch". Such compositions include, for example, lotions, creams, solutions, gels and solids. These topical compositions preferably comprise a safe and effective amount, usually at least about 0.1%, and preferably from
10 about 1% to about 5%, of the Formula (I) compound. Suitable carriers for topical administration preferably remain in place on the skin as a continuous film, and resist being removed by perspiration or immersion in water. Generally, the carrier is organic in nature and capable of having dispersed or dissolved therein the Formula (I) compound. The carrier may include pharmaceutically-acceptable emollients, emulsifiers, thickening agents, solvents
15 and the like.

VI. Methods of Administration:

 This invention also provides methods of treating or preventing disorders associated with excess or undesired metalloprotease activity in a human or other animal subject, by administering a safe and effective amount of a Formula (I) compound to said subject. As
20 used herein, a "disorder associated with excess or undesired metalloprotease activity" is any disorder characterized by degradation of matrix proteins. The methods of the invention are useful in treating or preventing disorders described above.

 Compositions of this invention can be administered topically or systemically. Systemic application includes any method of introducing Formula (I) compound into the
25 tissues of the body, e.g., intra-articular (especially in treatment of rheumatoid arthritis), intrathecal, epidural, intramuscular, transdermal, intravenous, intraperitoneal, subcutaneous, sublingual, rectal, and oral administration. The Formula (I) compounds of the present invention are preferably administered orally.

 The specific dosage of inhibitor to be administered, as well as the duration of
30 treatment, and whether the treatment is topical or systemic are interdependent. The dosage and treatment regimen will also depend upon such factors as the specific Formula (I) compound used, the treatment indication, the ability of the Formula (I) compound to reach minimum inhibitory concentrations at the site of the metalloprotease to be inhibited, the personal attributes of the subject (such as weight), compliance with the treatment regimen,
35 and the presence and severity of any side effects of the treatment.

 Typically, for a human adult (weighing approximately 70 kilograms), from about 5 mg to about 3000 mg, more preferably from about 5 mg to about 1000 mg, more preferably from about 10 mg to about 100 mg, of Formula (I) compound are administered

5 per day for systemic administration. It is understood that these dosage ranges are by way of example only, and that daily administration can be adjusted depending on the factors listed above.

A preferred method of administration for treatment of rheumatoid arthritis is oral or parenterally via intra-articular injection. As is known and practiced in the art, all
10 formulations for parenteral administration must be sterile. For mammals, especially humans, (assuming an approximate body weight of 70 kilograms) individual doses of from about 10 mg to about 1000 mg are preferred.

A preferred method of systemic administration is oral. Individual doses of from about 10 mg to about 1000 mg, preferably from about 10 mg to about 300 mg are preferred.

15 Topical administration can be used to deliver the Formula (I) compound systemically, or to treat a subject locally. The amounts of Formula (I) compound to be topically administered depends upon such factors as skin sensitivity, type and location of the tissue to be treated, the composition and carrier (if any) to be administered, the particular Formula (I) compound to be administered, as well as the particular disorder to be treated
20 and the extent to which systemic (as distinguished from local) effects are desired.

The inhibitors of the invention can be targeted to specific locations where the metalloprotease is accumulated by using targeting ligands. For example, to focus the inhibitors to metalloprotease contained in a tumor, the inhibitor is conjugated to an antibody or fragment thereof which is immunoreactive with a tumor marker as is generally understood in the
25 preparation of immunotoxins in general. The targeting ligand can also be a ligand suitable for a receptor which is present on the tumor. Any targeting ligand which specifically reacts with a marker for the intended target tissue can be used. Methods for coupling the invention compound to the targeting ligand are well known and are similar to those described below for coupling to carrier. The conjugates are formulated and administered as described above.

30 For localized conditions, topical administration is preferred. For example, to treat ulcerated cornea, direct application to the affected eye may employ a formulation as eyedrops or aerosol. For corneal treatment, the compounds of the invention can also be formulated as gels, drops or ointments, or can be incorporated into collagen or a hydrophilic polymer shield. The materials can also be inserted as a contact lens or reservoir or as a subconjunctival formulation.
35 For treatment of skin inflammation, the compound is applied locally and topically, in a gel, paste, salve or ointment. For treatment of oral diseases, the compound may be applied locally in a gel, paste, mouth wash, or implant. The mode of treatment thus reflects the nature of the condition and suitable formulations for any selected route are available in the art.

5 In all of the foregoing, of course, the compounds of the invention can be administered alone or as mixtures, and the compositions may further include additional drugs or excipients as appropriate for the indication.

Some of the compounds of the invention also inhibit bacterial metalloproteases. Some bacterial metalloproteases may be less dependent on the stereochemistry of the inhibitor, whereas
10 substantial differences are found between diastereomers in their ability to inactivate the mammalian proteases. Thus, this pattern of activity can be used to distinguish between the mammalian and bacterial enzymes.

VII. Preparation and Use of Antibodies:

Metalloproteases active at a particularly undesired location (e.g., an organ or certain
15 types of cells) can be targeted by conjugating the compounds of the invention to a targeting ligand specific for a marker at that location such as an antibody or fragment thereof or a receptor ligand. Conjugation methods are known in the art.

The invention is also directed to various other processes which take advantage of the unique properties of these compounds. Thus, in another aspect, the invention is directed to the
20 compounds of Formula (I) conjugated to solid supports. These conjugates can be used as affinity reagents for the purification of a desired metalloprotease.

In another aspect, the invention is directed to the compounds of Formula (I) conjugated to label. As the compounds of the invention bind to at least one metalloprotease, the label can be used to detect the presence of relatively high levels of metalloprotease *in vivo* or *in vitro* cell
25 culture.

In addition, the compounds of Formula (I) can be conjugated to carriers which permit the use of these compounds in immunization protocols to prepare antibodies specifically immunoreactive with the compounds of the invention. Typical conjugation methods are known in the art. These antibodies are then useful both in therapy and in monitoring the dosage of the
30 inhibitors.

The invention compounds can also be coupled to labels such as scintigraphic labels, e.g., technetium 99 or I-131, using standard coupling methods. The labeled compounds are administered to subjects to determine the locations of excess amounts of one or more metalloproteases *in vivo*. The ability of the inhibitors to selectively bind metalloprotease is thus
35 taken advantage of to map the distribution of these enzymes *in situ*. The techniques can also be employed in histological procedures and the labeled invention compounds can be used in competitive immunoassays.

The following non-limiting examples illustrate the compounds, compositions, and uses of the present invention.

VIII. Examples - Compound Preparation

The R groups used to illustrate the compound examples do not correlate to the respective R groups used to describe the various moieties of Formula (I). That is, for example, R¹, R² and R³ used to describe Formula (I) in Section II of the Detailed Description do not represent the same moieties as R₁, R₂, and R₃ in this Section VIII.

Typically tetrahydrofuran (THF) is distilled from sodium and benzophenone, diisopropylamine is distilled from calcium hydride and all other solvents are purchased as the appropriate grade. Chromatography is performed on silica gel (70 - 230 mesh; Aldrich) or (230 - 400 mesh; Merck) as appropriate. Thin layer chromatography analysis (TLC) is performed on glass mounted silica gel plates (200 - 300 mesh; Baker) and visualized with UV or 5% phosphomolybdic acid in ethanol (EtOH).

The following abbreviations are used herein:

MeOH: methanol	Et ₃ N: triethylamine
EtOAc: ethylacetate	Et ₂ O: diethylether
Ph: phenyl	boc: <i>t</i> -butyloxycarbonyl
DMF: N,N-dimethylformamide	acac: acetyl acetate
DME: dimethoxyethane	dil.: dilute
conc.: concentrated	wrt.: with respect to

Examples 1-52

The following chemical formula along with Table 1 shows the structure of compounds made according to the description in Examples 1-52 described below.




































































































Table 1

Example	R ₁	R ₂	R ₃
1		-H	

























2		-H	
3		-H	
4		-H	
5		-H	
6		-H	
7		-H	
8		-H	
9		-H	
10		-H	
11		-H	
12		-H	
13		-H	

14		-H	
15		-H	
16		-H	
17		-H	
18		-H	
19		-H	
20		-H	
21		-H	
22		-H	
23		-H	
24		-H	
25		-H	

26		-H	
27		-H	
28		-H	
29		-H	
30		-H	
31		-H	
32		-H	
33		-H	
34		-H	
35		-H	
36		-H	
37		-H	

38		-H	
39		-H	
40		-H	
41		-H	
42		-H	
43		-H	
44		-H	
45		-H	
46		-H	
47		-H	
48		-H	
49		-H	

-38-

50		-H	
51		-H	
52		-H	
53		-H	
54		-H	
55		-H	
56		-H	
57		-Me	
58		-Me	
59		-Me	
60		-H	
61		-Me	

Example 1**Preparation of 2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid**

- a. **N-Boc-allylglycine methyl ester:** To a mixture of acetyloxy[(1,1-dimethylethoxy)carbonyl]amino]acetic acid methyl ester (Ref. Tetrahedron Lett. 1994, 35 3669, 21.1 g, 85.7 mmol), zinc (11.2 g, 171.42 mmol) and DMF (100 mL) at 0° C is added allylbromide (14.8 mL, 171.4 mmol) dropwise. The reaction is warmed to room temperature and stirred overnight. The mixture is diluted with 0.1N HCl and hexane / EtOAc (2:1), filtered, the reaction mixture is then extracted three times with hexane / EtOAc (2:1). The combined EtOAc layer is washed twice with 0.1 N HCl, brine / H₂O, brine, dried over MgSO₄, and concentrated under reduced pressure to give an oil.
- b. **Methyl 2-[4-(iodophenyl)sulfonylamino]-pent-4-enoate:** To a solution of N-Boc-allylglycine methyl ester **1a** (19.6 g, 85.6 mmol) in CH₂Cl₂ (40 mL) at 0° C is added trifluoroacetic acid (33 mL, 428 mmol) slowly, and the resulting mixture is stirred overnight at room temperature. The reaction mixture is concentrated under reduced pressure to dryness then dissolved in dioxane (50 mL) and water (30 mL). To the solution is added triethylamine (35.7 mL, 256.8 mmol), followed by 4-iodobenzenesulfonyl chloride (28.6 g, 89.9 mmol) and the mixture is stirred overnight. The reaction mixture is diluted with water, and extracted three times with EtOAc. The combined EtOAc layer is washed consecutively with 1 N HCl, H₂O, and then brine. The organic layers are dried, and concentrated to an oil which solidifies upon standing to give the desired product.
- c. **Methyl 2-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonylamino]-pent-4-enoate:** To a solution of methyl 2-[4-(iodophenyl)sulfonylamino]-pent-4-enoate **1b** (35 g, 85.9 mmol) in benzene (400 mL), 2N NaHCO₃ (18 g, 171 mmol, in 65 mL of water) at room temperature is added slowly tetrakis(triphenylphosphine) palladium(0) (2.96 g, 2.5 mmol), followed by 4-methoxyphenylboronic acid (19.6 g, 128.4 mmol) in EtOH (40 mL). The reaction mixture is heated to reflux for 5.5 h. The solution is then cooled to room temperature, and H₂O₂ (4.4 mL, 43 mmol, 30% wt aqueous solution) is added to the reaction and the resulting mixture is stirred for 10 min and then diluted with water. The mixture is extracted three times with Et₂O. The combined Et₂O layer is washed with brine, dried over MgSO₄ and concentrated to a solid which is recrystallized from EtOAc / hexane to give the desired product.
- d. **Methyl 2-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4,5-epoxypentanoate:** To a solution of methyl 2-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonylamino]-pent-4-enoate **1c** (15.3 g, 40.8 mmol) in CH₂Cl₂ (150 mL), NaHCO₃ (7.1 g, 85 mmol) and water (80 mL) at 0° C, is added slowly *m*-chloroperbenzoic acid (32.6 g, ~123 mmol, 57 - 86%). The reaction mixture is stirred

overnight. The reaction is then diluted with aqueous NaHCO₃ and the mixture is extracted three times with EtOAc. The combined EtOAc layer is washed with NaHCO₃, brine, dried over MgSO₄ and concentrated to an oil. Purification is accomplished by column chromatography with EtOAc / hexane (3:7 to 6:4) as the eluent to give the desired product as a mixture of two isomers (ratio 2:3).

e. **3-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-[2-oxo-5-(thiazol-2-**

yl)thio]methyl]-tetrahydrofuran: To a solution of methyl 2-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4,5-epoxypentanoate **1d** (0.7 g, 1.79 mmol) in benzene (5 mL) and Et₃N (0.33 mL, 2.3 mmol) at room temperature is added slowly 2-mercaptothiazole (0.52 g, 4.48 mmol). The reaction mixture is stirred for 4 h at room temperature. The resulting mixture is diluted with water, and the mixture is then extracted three times with EtOAc. The combined EtOAc layer is consecutively washed with water, and brine, dried over MgSO₄ and concentrated to an oil under reduced pressure. Purification is accomplished by column chromatography with hexane / EtOAc (4:1 to 7:3 to 6:4) eluent to give the desired product.

f. **2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid:** To a solution of 3-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-[2-oxo-5-(thiazol-2-yl)thio]methyl]-tetrahydrofuran **1e** (0.38 g, 0.80 mmol) in water (5 mL) and THF (5 mL) is slowly added lithium hydroxide monohydrate (330 mg, 8 mmol). The reaction mixture is stirred for 2 h, then concentrated to dryness. The reaction is then diluted with water, and then the mixture is extracted twice with Et₂O. The Et₂O layer is discarded and the aqueous layer is neutralized carefully with 1N HCl to pH 6, and then extracted three times with EtOAc. The combined EtOAc layer is washed with brine, dried over MgSO₄ and concentrated to a solid which is recrystallized from EtOAc / hexane to give the desired product as a white solid.

Example 2

2-[(4'-(Methylthio)[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid

Example 2 is prepared from 4-(methylthio)phenylboronic acid and **1c** using the procedure described for compound **1**.

Example 3

2-[(4'-Phenoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid

Example 3 is prepared from 4-(phenoxy)phenylboronic acid and **1c** using the procedure described for compound **1**.

Example 4

2-[(4'-(2-Methoxyethoxy)[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid

Example 4 is prepared from 4-(2-methoxyethoxy)phenylboronic acid and 1c using the procedure described for compound 1.

Example 5

2-[(4'-(2-(1-Pyrrolidiny)ethoxy)[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid

Example 5 is prepared from 4-(2-(1-pyrrolidiny)ethoxy)phenylboronic acid and 1c using the procedure described for compound 1.

Example 6

2-[(1,1':4',1''-Terphenyl)-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid

Example 6 is prepared from 4-biphenylboronic acid and 1c using the procedure described for compound 1.

Example 7

2-[(3',4'-(Methylenedioxy)[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid

Example 7 is prepared from 4-methylenedioxyphenylboronic acid and 1c using the procedure described for compound 1.

Example 8

2-[(3'-Ethoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid

Example 8 is prepared from 3-ethoxyphenylboronic acid and 1c using the procedure described for compound 1.

Example 9

2-[[4-[(4-Methoxyphenyl)ethynyl]phenyl]sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid

Example 9 is prepared from 1-ethynyl-4-methoxybenzene and 1c using the procedure described for compound 1.

Example 10

2-[[4-[(4-Methylphenyl)ethynyl]phenyl]sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid

Example 10 is prepared from 1-ethynyltoluene and 1c using the procedure described for compound 1.

Example 11

2-[[4-(Phenylazo)phenyl]sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid

Example 11 is prepared from 4-phenylazobenzene sulfonyl chloride and 1a using the procedure described for compound 1.

Example 12

2-[(4'-Chloro[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-thiazolylthio]-pentanoic acid

a. **4'-Chlorobiphenyl-4-sulfonic acid:** To a solution of 4-chlorobiphenyl (15 g, 79.8 mmol) in chloroform (150 mL) is added dropwise chlorosulfonic acid (11.2 g, 96 mmol). A white solid precipitate forms during the addition. The reaction is stirred at room temperature for 6 hr, at which time the precipitate is collected by filtration and the precipitate is then washed with cold chloroform. The product is dried under vacuum to give a white solid product. The product is used without further purification.

b. **4'-Chlorobiphenyl-4-sulfonyl chloride:** To a solution of 4'-chlorobiphenyl-4-sulfonic acid 12a (15.1 g, 78.1 mmol) in thionyl chloride (150 mL) is added a catalytic amount of N,N-dimethylformamide (0.3 mL). The reaction mixture is heated to reflux for 4 hr. The mixture is then cooled to room temperature, and concentrated under reduced pressure. Toluene is then added and the mixture is concentrated under reduced pressure. The solid crude product is then recrystallized with ethyl acetate and hexanes to give the solid desired product.

c. **Methyl 2-[4'-(chloro[1',1'-biphenyl]-yl)-4-sulfonylamino]-pent-4-enoate:** To a solution of allylglycine methyl ester hydrochloride (5 g, 30.2 mmol) in CH₂Cl₂ (150 mL) at 0 °C is added triethylamine (9.2 g, 90.6 mmol), followed by 4-chlorobiphenyl-4-sulfonyl chloride 12b (9.1 g, 31.7 mmol) and the mixture is allowed to warm to room temperature and is stirred overnight. The reaction mixture is diluted with water, extracted 3 times with ethyl acetate. The combined ethyl acetate layer is washed with 1 N HCl and brine. The organic layers are dried with MgSO₄, filtered, and concentrated to an oil which is allowed to stand and solidify to the desired product.

- 5 d. **Methyl 2-[(4'-chloro[1,1'-biphenyl]-4-yl)-sulfonyl]amino-4,5-epoxypentanoate:** To a solution of methyl 2-[(4'-chloro[1,1'-biphenyl]-4-yl)-sulfonylamino]-pent-4-eneoate **12c** (9.2 g, 24.1 mmol) in CH₂Cl₂ (175 mL), NaHCO₃ (4.2 g, 50 mmol) and water (100 mL) at 0 C, is slowly added m-chloroperbenzoic acid (57-86%) (19.4 g, ~80 mmol). The reaction is stirred for 72 hours. The mixture is diluted with aqueous NaHCO₃ and this mixture is extracted with ethyl acetate (3 x 100 mL). The combined ethyl acetate layer is washed with brine, dried over MgSO₄,
10 filtered and concentrated to an oil. Purification of this compound is accomplished by column chromatography with 40% ethyl acetate in hexanes as the eluent to give the desired product.
- e. **3-[(4'-Chloro[1,1'-biphenyl]-4-yl)sulfonyl]amino-[2-oxo-5-(thiazol-2-yl)thio]methyl]-tetrahydrofuran:** To a solution of methyl 2-[(4'-chloro[1,1'-biphenyl]-4-yl)amino-4,5-epoxypentanoate **12d** (2.6 g, 6.5 mmol) in benzene (10 mL) and triethylamine (0.95 mL, 6.85 mmol) at room temperature is added slowly 2-mercaptothiazole (1.52 g, 13 mmol). The reaction is stirred overnight at room temperature. The resulting mixture is diluted with water and the mixture is then extracted with ethyl acetate (3 x 50 mL). The combined ethyl acetate layer is washed with brine, dried of MgSO₄, filtered and concentrated to an oil under reduced
15 pressure. Purification is done by column chromatography with 30% ethyl acetate in hexanes to 40% ethyl acetate in hexanes as the eluent to give the desired product.
- f. **2-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-thiazolylthio]-pentanoic acid:** To a solution of 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]amino-[2-oxo-5-(thiazol-2-yl)thio]methyl]-tetrahydrofuran **12e** (1.30 g, 2.7 mmol) in water (7 mL) and THF (7 mL) is slowly added lithium hydroxide (0.65 g, 27 mmol). The reaction is stirred for 4 hr, then
20 concentrated to dryness. The reaction mixture is diluted with water and then the mixture is extracted with ethyl ether (2 x 25 mL) The ethyl ether layer is discarded and the aqueous layer is slowly acidified with 1N HCl to pH 5, and then extracted 3 times with ethyl acetate. The combined ethyl acetate layers are washed with water and brine, dried over MgSO₄, filtered and
25 concentrated under reduced pressure. The white solid is then recrystallized with ethyl acetate/hexanes to give the desired product as a white solid.

Example 13

2-[(4'-Bromo[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-thiazolylthio]-pentanoic acid

- 35 a. **4'-Bromobiphenyl-4-sulfonic acid:** To a solution of 4-bromobiphenyl (18.6 g, 79.8 mmol) in chloroform (150 mL) is added dropwise chlorosulfonic acid (11.2 g, 96 mmol). A white solid precipitate forms during the addition. The reaction is stirred at room temperature for 6 hr, at which time the precipitate is collected by filtration and the precipitate is then washed with

5 cold chloroform. The product is dried under vacuum to give a white solid product. The product is used without further purification.

b. **4'-Bromobiphenyl-4-sulfonyl chloride:** To a solution of 4'-bromobiphenyl-4-sulfonic acid 13a (18.8 g, 78.1 mmol) in thionyl chloride (150 mL) is added a catalytic amount of N,N-dimethylformamide (0.3 mL). The reaction mixture is heated to reflux for 4 hr. The mixture is
10 then cooled to room temperature, and concentrated under reduced pressure. Toluene is then added and the mixture is concentrated under reduced pressure. The solid crude product is then recrystallized with ethyl acetate and hexanes to give the solid desired product.

c. **Methyl 2-[4'-(bromo[1',1'-biphenyl]-yl)-4-sulfonylamino]-pent-4-enoate:** To a solution of allylglycine methyl ester hydrochloride (5 g, 30.2 mmol) in CH₂Cl₂ (150 mL) at 0° C
15 is added triethylamine (9.2 g, 90.6 mmol), followed by 4-bromobiphenyl-4-sulfonyl chloride 13b (10.5 g, 31.7 mmol) and the mixture is allowed to warm to room temperature and is stirred overnight. The reaction mixture is diluted with water, extracted 3 times with ethyl acetate. The combined ethyl acetate layer is washed with 1 N HCl and brine. The organic layers are dried with MgSO₄, filtered, and concentrated to an oil which is allowed to stand and solidifies to the
20 desired product.

d. **Methyl 2-[(4'-bromo[1,1'-biphenyl]-4-yl)-sulfonyl]amino-4,5-epoxypentanoate:** To a solution of methyl 2-[(4'-bromo[1,1'-biphenyl]-4-yl)-sulfonylamino]-pent-4-eneoate 13c (10.2 g, 24.1mmol) in CH₂Cl₂ (150 mL), NaHCO₃ (11.0 g, 50 mmol) and water (140 mL) at 0° C, is slowly added m-chloroperbenzoic acid (57-86%) (19.4 g, ~80 mmol). The reaction is stirred for
25 72 hours. The mixture is diluted with aqueous NaHCO₃ and this mixture is extracted with ethyl acetate (3 x 250 mL). The combined ethyl acetate layer is washed with brine, dried over MgSO₄, filtered and concentrated to an oil. Purification of this compound is accomplished by column chromatography with 40% ethyl acetate in hexanes as the eluent to give the desired product.

e. **3-[(4'-Bromo[1,1'-biphenyl]-4-yl)sulfonyl]amino-[2-oxo-5-(thiazol-2-yl)thio]methyl-tetrahydrofuran:** To a solution of methyl 2-[(4'-bromo[1,1'-biphenyl]-4-yl)amino-4,5-epoxypentanoate 13d (2.4 g, 5.4 mmol) in benzene (20 mL) and triethylamine (0.96 mL, 6.9 mmol) at room temperature is added slowly 2-mercaptothiazole (1.23 g, 10.5 mmol). The reaction is stirred overnight at room temperature. The resulting mixture is diluted with water and the mixture is then extracted with ethyl acetate (3 x 50 mL). The combined ethyl
35 acetate layer is washed with brine, dried of MgSO₄, filtered and concentrated to an oil under reduced pressure. Purification is done by column chromatography with 30% ethyl acetate in hexanes to 40% ethyl acetate in hexanes as the eluent to give the desired product.

- 5 f. **2-[(4'-bromo[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-thiazolylthio]-pentanoic acid:** To a solution of 3-[(4'-bromo[1,1'-biphenyl]-4-yl)sulfonyl]amino-[2-oxo-5-(thiazol-2-yl)thio]methyl]-tetrahydrofuran 13e (1.58 g, 3.1 mmol) in water (8 mL) and THF (8 mL) is slowly added lithium hydroxide (0.74 g, 31 mmol). The reaction is stirred for 4 hr, then concentrated to dryness. The reaction mixture is diluted with water and then the mixture is
10 extracted with ethyl ether (2 x 25 mL). The ethyl ether layer is discarded and the aqueous layer is slowly acidified with 1N HCl to pH 5, and then extracted 3 times with ethyl acetate. The combined ethyl acetate layers are washed with water and brine, dried over MgSO₄, filtered and concentrated under reduced pressure. The white solid is then recrystallized with ethyl acetate/hexanes to give the desired product as a white solid.

15

Example 14

2-[(4'-Trifluoromethyl[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-thiazolylthio]-pentanoic acid

- a. **Methyl 2-[(4'-trifluoromethyl[1,1'-biphenyl]-4-yl]amino-4-penteneoate:** To a solution of methyl 2-[4-(bromophenyl)sulfonyl]amino-4-penteneoate (3.2 g, 9.1 mmol) in
20 benzene (80 mL), NaHCO₃ (2.08 g, 20 mmol), and 10 mL of water, is slowly added tetrakis(triphenylphosphine)palladium (0) (0.034 g, 0.03 mmol), followed by 4-trifluoromethylphenylboronic acid (2.8 g, 14.6 mmol). The reaction is stirred and heated to reflux and it is refluxed overnight. The reaction mixture is allowed to cool to room temperature. 1 N HCl (20 mL) is then added to the reaction and stirred and the mixture is then diluted with
25 water. The mixture is extracted with ethyl acetate three times. The combined ethyl acetate layers are washed with brine, dried over MgSO₄, filtered and concentrated under reduced pressure to a solid. Purification is done by column chromatography with 30% ethyl acetate in hexane as the eluent to give the desired product.
- b. **Methyl 2-[(4'-trifluoromethyl[1,1'-biphenyl]-4-yl]amino-4,5-epoxypentaneate:** To a
30 solution of methyl 2-[(4'-trifluoromethyl[1,1'-biphenyl]-4-yl]amino-4-penteneoate 14a (3.5 g, 8.4 mmol) in CH₂Cl₂ (50 mL), NaHCO₃ (2.6 g, 25.2 mmol) and water (30 mL) at 0° C, is slowly added m-chloroperbenzoic acid (57-86%) (7.3 g, ~30 mmol). The reaction is stirred for 72 hours. The mixture is diluted with aqueous NaHCO₃ and this mixture is extracted with ethyl acetate (3 x 250 mL). The combined ethyl acetate layer is washed with brine, dried over MgSO₄, filtered and
35 concentrated to an oil. Purification of this compound is accomplished by column chromatography with 40% ethyl acetate in hexanes as the eluent to give the desired product.

5 c. **3-[(4'-Trifluoromethyl[1,1'-biphenyl]-4-yl)sulfonyl]amino-[2-oxo-5-(thiazol-2-yl)thio]methyl]-tetrahydrofuran:** To a solution of methyl 2-[(4'-trifluoromethyl[1,1'-biphenyl]-4-yl)amino-4,5-epoxypentanoate **14b** (1.76 g, 4.1 mmol) in benzene (15 mL) and triethylamine (0.74 mL, 5.3 mmol) at room temperature is added slowly 2-mercaptothiazole (0.96 g, 8.2 mmol). The reaction is stirred overnight at room temperature. The resulting mixture
10 is diluted with water and the mixture is then extracted with ethyl acetate (3 x 50 mL). The combined ethyl acetate layer is washed with brine, dried of MgSO_4 , filtered and concentrated to an oil under reduced pressure. Purification is done by column chromatography with 30% ethyl acetate in hexanes to 40% ethyl acetate in hexanes as the eluent to give the desired product.

d. **2-[(4'-Trifluoromethyl[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-benzothiazolylthio]-pentanoic acid:** To a solution of 3-[(4'-trifluoromethyl[1,1'-biphenyl]-4-yl)sulfonyl]amino-[2-oxo-5-(thiazol-2-yl)thio]methyl]-tetrahydrofuran **14c** (1.13 g, 2.2 mmol) in
15 water (5 mL) and THF (5 mL) is slowly added lithium hydroxide (0.53 g, 22 mmol). The reaction is stirred for 2 hr, then concentrated to dryness. The reaction mixture is diluted with water and then the mixture is extracted with ethyl ether (2 x 25 mL). The ethyl ether layer is
20 discarded and the aqueous layer is slowly acidified with 1N HCl to pH 5, and then extracted 3 times with ethyl acetate. The combined ethyl acetate layers are washed with water and brine, dried over MgSO_4 , filtered and concentrated under reduced pressure. The solid is purified by prep HPLC to give the desired white solid product.

Example 15

25 **2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-(phenylthio)-pentanoic acid**

a. **3-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-2-oxo-5-[(phenylthio)methyl]-tetrahydrofuran:** To a solution of methyl 2-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4,5-epoxypentanoate **1d** (0.5 g, 1.28 mmol) in benzene (5 mL) and Et_3N (0.23 mL, 1.66 mmol) at room temperature is added slowly benzenethiol (0.33 mL, 3.2 mmol). The reaction mixture is
30 stirred overnight. The resulting mixture is diluted with water, and then the mixture is extracted three times with EtOAc. The combined EtOAc layer is washed with water, brine, dried over MgSO_4 and concentrated to an oil which is purified by column chromatography eluting with EtOAc / hexane (3:7) to give the desired product as a mixture of two isomers (ratio: ~4:1).

b. **2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-(phenylthio)-pentanoic acid:** To a solution of 3-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-2-oxo-5-
35 [(phenylthio)methyl]-tetrahydrofuran **12a** (0.26 g, 0.55 mmol) in water (5 mL) and THF (5 mL) is added slowly lithium hydroxide monohydrate (230 mg, 5.5 mmol). The reaction mixture is stirred overnight, and then concentrated to dryness. The resulting mixture is diluted with water,

5 and then the mixture is extracted twice with Et₂O. The Et₂O layer is discarded and the aqueous layer is neutralized carefully with 1N HCl to pH 6, then extracted three times with EtOAc. The combined EtOAc layer is washed with brine, dried over MgSO₄ and concentrated to a solid which is recrystallized from EtOAc / hexane to give the desired product as a white solid.

Example 16

10 2-[[[(1,1'-biphenyl)-4-yl]sulfonyl]amino-4-hydroxy-5-(phenylthio)-pentanoic acid

a. **Methyl 2-[[[(1,1'-biphenyl)-4-yl]sulfonyl]amino-4-pentenoate:** To a solution of N-Boc-allylglycine methyl ester **1a** (4.0 g, 17.6 mmol) in CH₂Cl₂ (15 mL) is added trifluoroacetic acid (10 mL) slowly, and the resulting mixture is stirred overnight at room temperature. The reaction mixture is concentrated under reduced pressure to dryness then dissolved in dioxane (15 mL) and water (15 mL). To the solution is added triethyl amine (9.8 mL, 70.4 mmol), followed by biphenyl-4-sulfonyl chloride (5.9 g, 21.12 mmol) and the mixture is stirred overnight. The reaction mixture is diluted with water, extracted three times with EtOAc. The combined EtOAc layer is washed with 1 N HCl, H₂O, brine, dried, and concentrated to an oil which solidified upon standing. The crude product is recrystallized from EtOAc / hexane to give the desired product.

15 b. **Methyl 2-[[[(1,1'-biphenyl)-4-yl]sulfonyl]amino-4,5-epoxypentanoate:** To a solution of methyl 2-[[[(1,1'-biphenyl)-4-yl]sulfonyl]amino-4-pentenoate **16a** (2.0 g, 5.8 mmol) in CH₂Cl₂ (15 mL), NaHCO₃ (0.58 g, 7 mmol) and water (10 mL) at 0°C, is added slowly *m*-chloroperbenzoic acid (3.3 g, 11.6 mmol, 57 - 86%). The reaction mixture is stirred overnight. The resulting mixture is diluted with aqueous NaHCO₃, and the mixture is extracted three times with CH₂Cl₂. The combined CH₂Cl₂ layers are washed with NaHCO₃, brine, dried over MgSO₄ and concentrated to an oil which is purified by column chromatography eluting with EtOAc / hexane (4:6) to give the desired product as a mixture of two isomers (ratio 2:3).

20 c. **3-[[[(1,1'-Biphenyl)-4-yl]sulfonyl]amino-2-oxo-5-[(phenylthio)methyl]-tetrahydrofuran:** To a solution of methyl 2-[[[(1,1'-biphenyl)-4-yl]sulfonyl]amino-4,5-epoxypentanoate **16b** (0.36 g, 1.47 mmol) in benzene (5 mL) and Et₃N (0.27 g, 1.91 mmol) at room temperature is added slowly benzenethiol (0.38 mL, 3.67 mmol). The reaction mixture is stirred for 3 hrs. The resulting mixture is diluted with water, and then the mixture is extracted three times with EtOAc. The combined EtOAc layer is washed with water, brine, dried over MgSO₄ and concentrated to an oil which is purified by column chromatography eluting with EtOAc / hexane (1:4 to 3:7) to give the desired product as a mixture of two isomers (ratio: ~2:1).

35 d. **2-[[[(1,1'-Biphenyl)-4-yl]sulfonyl]amino-4-hydroxy-5-(phenylthio)-pentanoic acid:** To a solution of 3-[[[(1,1'-biphenyl)-4-yl]sulfonyl]amino-2-oxo-5-[(phenylthio)methyl]-tetrahydrofuran **16c** (0.18 g, 0.41 mmol) in water (5 mL) and THF (5 mL) is added slowly

5 lithium hydroxide monohydrate (172 mg, 4.1 mmol). The reaction mixture is stirred for 3 hr, then concentrated to dryness. The resulting mixture is diluted with water, and then the mixture is extracted twice with Et₂O. The Et₂O layer is discarded and the aqueous layer is neutralized carefully with 1N HCl to pH 6, then extracted three times with EtOAc. The combined EtOAc layer is washed with brine, dried over MgSO₄, and concentrated to a solid which is recrystallized
10 from EtOAc / hexane to give the desired product.

Example 17

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-(benzylthio)-pentanoic acid

a. **3-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-2-oxo-5-[(benzylthio)methyl]-
15 tetrahydrofuran:** To a solution of methyl 2-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4,5-epoxypentanoate **1d** (0.5 g, 1.28 mmol) in benzene (3 mL), NaHCO₃ (0.32 g, 3.84 mmol) and Et₃N (0.23 mL, 1.6 mmol) at room temperature is added slowly benzyl mercaptan (0.62 mL, 4.99 mmol). The reaction mixture is heated at 70°C for 3 h, and stirred two days at room temperature. The resulting mixture is diluted with water, and then the mixture is extracted three times with
20 EtOAc. The combined EtOAc layer is washed with water, brine, dried over MgSO₄, and concentrated to an oil which is purified by column chromatography eluting with hexane / EtOAc (4:1) to give the desired product.

b. **2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-(benzylthio)-
pentanoic acid:** To a solution of 3-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-2-oxo-5-
25 [(benzylthio)methyl]-tetrahydrofuran **17a** (40 mg, 0.083 mmol) in water (3 mL) and THF (3 mL) is added slowly lithium hydroxide monohydrate (35 mg, 0.82 mmol). The reaction mixture is stirred overnight, then concentrated to dryness. The resulting mixture is diluted with water, and then the mixture is extracted twice with Et₂O. The Et₂O layer is discarded and the aqueous layer is neutralized carefully with 1N HCl to pH 6, then extracted three times with EtOAc. The
30 combined EtOAc layer is washed with brine, dried over MgSO₄, and concentrated to a solid which is recrystallized from EtOAc / hexane (1:4) to give the desired product as a white solid.

Example 18

**2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(benzyl)sulfonyl]-
pentanoic acid**

35 To a stirred solution of 2-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-(benzylthio)-pentanoic acid **17b** (0.57 g, 1.13 mmol) in CH₂Cl₂ (10 mL) is added slowly peracetic acid (0.55 mL, 2.32 mmol). The reaction is stirred until analytical HPLC showed the

starting material is gone. After stirring overnight, water is added to dilute the reaction mixture. The mixture is extracted with ethyl acetate (3 x 25 mL). The combined ethyl acetate layer is washed with brine, dried with MgSO₄, filtered, and concentrated under reduced pressure to a white solid. Purification is accomplished by prep HPLC to give the desired product as a white solid.

Example 19

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-(phenylamino)-pentanoic acid

a. **3-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-2-oxo-5-[(phenylamino)methyl]-tetrahydrofuran:** To a solution of methyl 2-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4,5-epoxypentanoate **1d** (0.5 g, 1.28 mmol) in aniline (0.17 mL, 1.92 mmol) is added magnesium perchlorate (2 mg, 0.009 mmol) and the resulting mixture is heated for 4 h at 80°C. The resulting mixture is cooled to room temperature, and then the mixture is diluted with water, and extracted three times with EtOAc. The combined EtOAc layer is washed with water, brine, dried over MgSO₄ and concentrated to an oil which is purified by column chromatography eluting with hexane / EtOAc (7:3) to give the desired product.

b. **2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-(phenylamino)-pentanoic acid:** To a solution of 3-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-2-oxo-5-[(phenylamino)methyl]-tetrahydrofuran **19a** (0.19 g, 0.42 mmol) in water (3 mL) and THF (3 mL) is added slowly lithium hydroxide monohydrate (180 mg, 4.2 mmol). The reaction mixture is stirred for 4 h, and then concentrated to dryness. The resulting mixture is diluted with water, and then the mixture is extracted twice with Et₂O. The Et₂O layer is discarded and the aqueous layer is neutralized carefully with 1N HCl to pH 6, then extracted three times with EtOAc. The combined EtOAc layer is washed with brine, dried over MgSO₄ and concentrated to a solid which is recrystallized from EtOAc / hexane (3:7) to give the desired product as a white solid.

Example 20

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(1H-1,2,4-triazol-3-yl)thio]-pentanoic acid

a. **3-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-2-oxo-5-[(1H-1,2,4-triazol-3-ylthio)methyl]-tetrahydrofuran:** To a solution of methyl 2-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4,5-epoxypentanoate **1d** (0.7 g, 1.79 mmol) in benzene (6 mL) and Et₃N (0.33 mL, 2.3 mmol) at room temperature is added slowly 1H-1,2,4-mercaptotriazole (0.47 g, 4.48 mmol). The reaction mixture is stirred overnight at room temperature. Diluted with water, the

5 mixture is extracted three times with EtOAc. The combined EtOAc layer is washed with water, brine, dried over MgSO_4 and concentrated to an oil which is purified by column chromatography eluting with hexane / EtOAc (1:1) to give the desired product.

b. **2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(1H-1,2,4-triazol-3-yl)thio]-pentanoic acid:** To a solution of 3-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-2-oxo-5-[(1H-1,2,4-triazol-3-ylthio)methyl]-tetrahydrofuran **20a** (0.34 g, 0.68 mmol) in water (5 mL) and THF (5 mL) is added slowly lithium hydroxide monohydrate (290 mg, 4.2 mmol). The reaction mixture is stirred for 4 h, then concentrated to dryness. Diluted with water, the mixture is extracted twice with Et_2O . The Et_2O layer is discarded and the aqueous layer is neutralized carefully with 1N HCl to pH 6, then extracted three times with EtOAc. The combined EtOAc layer is washed with brine, dried over MgSO_4 and concentrated to a solid which is recrystallized from EtOAc / hexane (1:4) to give the desired product as a white solid.

Example 21

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-(phenylamino)-pentanoic acid

20 Example 21 is prepared from N-methylaniline and **1d** using the procedure described for compound **19**.

Example 22

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-imidazolyl)thio]-pentanoic acid

25 Example 22 is prepared from 2-mercaptoimidazole and **1d** using the procedure described for compound **20**.

Example 23

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[[2-(5-methylbenzimidazolyl)]thio]-pentanoic acid

30 Example 23 is prepared from 2-mercapto-5-benzimidazole and **1d** using the procedure described for compound **20**.

Example 24

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(4(3H)-quinazolinonyl)thio]-pentanoic acid

- 5 Example 24 is prepared from 2-mercapto-4(3H)-quinazolinone and 1d using the procedure described for compound 20.

Example 25

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(6-ethoxy-2-benzothiazolyl)thio]-pentanoic acid

- 10 Example 25 is prepared from 6-ethoxy-2-mercaptobenzothiazole and 1d using the procedure described for compound 20.

Example 26

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-benzothiazolylthio]-pentanoic acid

- 15 Example 26 is prepared from 2-mercaptobenzothiazole and 1d using the procedure described for compound 20.

Example 27

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-benzoxazolylthio]-pentanoic acid

- 20 Example 27 is prepared from 2-mercaptobenzoxazole and 1d using the procedure described for compound 20.

Example 28

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-benzimidazolylthio]-pentanoic acid

- 25 Example 28 is prepared from 2-mercaptobenzimidazole and 1d using the procedure described for compound 20.

Example 29

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-(1-methyl-1H-imidazol-2-yl)thio]-pentanoic acid

- 30 Example 29 is prepared from 2-mercapto-1-methylimidazole and 1d using the procedure described for compound 20.

5

Example 30

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(1-methyl-1H-tetrazol-5-yl)thio]-pentanoic acid

Example 30 is prepared from 5-mercapto-1-methyltetrazole and 1d using the procedure described for compound 20.

10

Example 31

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]-pentanoic acid

Example 31 is prepared from 5-methyl-1,3,4-thiadiazole-2-thiol and 1d using the procedure described for compound 20.

15

Example 32

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(4-methyl-4(H)-1,2,4-triazol-3-yl)thio]-pentanoic acid

Example 32 is prepared from 4-methyl-4H-1,2,4-triazole-3-thiol and 1d using the procedure described for compound 20.

20

Example 33

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(5-(methylthio)-1,3,4-thiadiazol-2-yl)thio]-pentanoic acid

Example 33 is prepared from 5-(methylthio)-1,3,4-thiadiazole-2-thiol and 1d using the procedure described for compound 20.

25

Example 34

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-thienylthio]-pentanoic acid

Example 34 is prepared from 2-thiophenethiol and 1d using the procedure described for compound 20.

30

Example 35

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(5-phenyl-1,3,4-oxadiazol-2-yl)thio]-pentanoic acid

- 5 Example 35 is prepared from 5-phenyl-1,3,4-oxadiazole-2-thiol and 1d using the procedure described for compound 20.

Example 36

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(1-(4-methoxyphenyl)-1H-tetrazol-1-yl)thio]-pentanoic acid

- 10 Example 36 is prepared from 5-mercapto-1-(4-methoxyphenyl)-1H-tetrazole and 1d using the procedure described for compound 20.

Example 37

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(6-chloro-2-benzoxazolyl)thio]-pentanoic acid

- 15 Example 37 is prepared from 6-chloro-2-benzoxazolethiol and 1d using the procedure described for compound 20.

Example 38

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[[3-(methylthio)-1,2,4-thiadiazol-5-yl]thio]-pentanoic acid

- 20 Example 38 is prepared from 3-methylmercapto-5-mercapto-1,2,4-thiadiazole and 1d using the procedure described for compound 20.

Example 39

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[[5-(4-pyridinyl)-1,3,4-oxadiazol-2-yl]thio]-pentanoic acid

- 25 Example 39 is prepared from 5-(4-pyridinyl)-1,3,4-oxadiazole-2-thiol and 1d using the procedure described for compound 20.

Example 40

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(5-methoxybenzothiazolyl-2-yl)thio]-pentanoic acid

- 30 Example 40 is prepared from 2-mercapto-5-methoxybenzothiazole and 1d using the procedure described for compound 20.

5

Example 41

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(5-methoxy-benzimidazol-2-yl)thio]-pentanoic acid

Example 41 is prepared from 5-methoxy-2-benzimidazolethiol and 1d using the procedure described for compound 20.

10

Example 42

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(5-phenyl-1H-1,2,4-triazol-3-yl)thio]-pentanoic acid

Example 42 is prepared from 5-phenyl-1H-1,2,4-triazole-3-thiol and 1d using the procedure described for compound 20.

15

Example 43

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-methyl-3-furanyl)thio]-pentanoic acid

Example 43 is prepared from 2-methyl-3-furanthiol and 1d using the procedure described for compound 20.

20

Example 44

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(4-methoxyphenyl)thio]-pentanoic acid

Example 44 is prepared from 4-methoxybenzenethiol and 1d using the procedure described for compound 20.

25

Example 45

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[pyrimidin-2-ylthio]-pentanoic acid

Example 45 is prepared from 2-mercaptopyrimidine and 1d using the procedure described for compound 20.

30

Example 46

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[4,6-dimethylpyrimidin-2-ylthio]-pentanoic acid

- 5 Example 46 is prepared from 4,6-dimethyl-2-mercaptopyrimidine and 1d using the procedure described for compound 20.

Example 47

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[pyridin-2-ylthio]-pentanoic acid

- 10 Example 47 is prepared from 2-mercaptopyridine and 1d using the procedure described for compound 20.

Example 48

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[purin-2-ylthio]-pentanoic acid

- 15 Example 48 is prepared from 2-mercaptopurine and 1d using the procedure described for compound 20.

Example 49

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[4-methylcoumarin-7-ylthio]-pentanoic acid

- 20 Example 49 is prepared from 7-mercapto-4-methylcoumarin and 1d using the procedure described for compound 20.

Example 50

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[[4-methoxyphenyl)methyl]thio]-pentanoic acid

- 25 Example 50 is prepared from 4-methoxy- α -toluenethiol and 1d using the procedure described for compound 20.

Example 51

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[[4-fluorophenyl)methyl]thio]-pentanoic acid

- 30 Example 51 is prepared from 4-fluorobenzylmercaptan and 1d using the procedure described for compound 20.

5

Example 52

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[furfurylthio]-pentanoic acid

Example 52 is prepared from furfuryl mercaptan and 1d using the procedure described for compound 20.

10

Example 53

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thienyl)methylthio]-pentanoic acid

Example 53 is prepared from 2-thienylmercaptan and 1d using the procedure described for compound 20.

15

Example 54

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-phenoxy-pentanoic acid

Example 54 is prepared from phenol and 1d using the procedure described for compound 20.

Example 55

20

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[pyridin-3-yloxy]-pentanoic acid

Example 55 is prepared from 3-hydroxypyridine and 1d using the procedure described for compound 20.

Example 56

25

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[pyrimidin-2-yloxy]-pentanoic acid

Example 56 is prepared from 2-hydroxypyrimidine and 1d using the procedure described for compound 20.

Example 57

30

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-4-methyl-5-[(1-N-methyl-imidazol-2-yl-thio)-methyl]-pentanoic acid

a. Methyl 2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-methylpent-4-enoate: The starting methyl 2-*tert*-butoxycarbonylamino-4-methylpent-4-enoate (6.0 g, 24.7 mmol; *Tetrahedron* 1997, 33, 88; *Tetrahedron Lett* 1994, 3669) is taken in 100 mL of methylene chloride, treated with 10 mL of trifluoroacetic acid, stirred for three hr., evaporated to dryness

-57-

5 and triturated twice with chloroform. The residue is then taken in 210 mL of methylene chloride in the presence of 21 mL of triethylamine, treated with (4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl chloride, stirred for three days and concentrated. The residue is then partitioned between EtOAc and 1N HCl and the organic layer is washed with 1N HCl, washed with brine, dried over MgSO₄, filtered and evaporated. The resulting material is then purified over flash silica with
10 hexanes:EtOAc (7:3) to give a white solid.

b. Methyl 2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-methyl-4,5-epoxy-pentanoate: The starting olefin 57a (2.6 g, 6.68 mmol) is taken in methylene chloride and treated with *meta*-chloroperoxybenzoic acid (4.7 g, 27 mmol). The resulting solution is stirred for 18 hr., diluted with methylene chloride, washed 2 times with dilute Na₂CO₃, dried over
15 MgSO₄, filtered and evaporated to give a solid residue which is purified over flash silica with hexanes:EtOAc (7:3) to give a white solid.

c. 3-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-2-oxo-5-methyl-5-[(1-*N*-Methyl-imidazol-2-yl-thio)-methyl]-tetrahydrofuran: The starting epoxide 57b is opened with 1-*N*-methyl-2-mercaptoimidazole as described for compound 1e to give a white solid.

20 **d.** The starting ester 57c is hydrolyzed as described for compound 1f to give the title acid as a white solid.

Example 58

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-4-methyl-5-[(thiazol-2-yl)-thiomethyl]-pentanoic acid

25 The starting epoxide 57b is opened with 2-mercaptothiazol as described for compound 1e and the resulting product is hydrolyzed as described for compound 1f to give the title acid as a white solid.

Example 59

30 **2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-4-methyl-5-[(1*H*-1,2,4-triazol-5-yl)-thiomethyl]-pentanoic acid**

The starting epoxide 57b is opened with 5-mercapto-1*H*-1,2,4-triazole as described for compound 1e and the resulting product is hydrolyzed as described for compound 1f to give the title acid as a white solid.

Example 60

5 **2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-4-methyl-5-[(3-trifluoromethylpyridin-2-yl)-thiomethyl]-pentanoic acid**

The starting epoxide **57b** is opened with 2-mercapto-3-trifluoromethylpyridin as described for compound **1e** and the resulting product is hydrolyzed as described for compound **1f** to give the title acid as a white solid.

10

Example 61

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(3-trifluoromethyl)-2-pyridyl-thio]-pentanoic acid


a. **3-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-2-oxo-5-[(3-trifluoromethyl)-2-pyridyl-thio]methyl-tetrahydrofuran:** To a solution of methyl 2-[(4'-methoxy[1,1'-biphenyl]-4-yl]amino-4,5-epoxypentanoate **1d** (1.9 g, 5.1 mmol) in benzene (25 mL) and triethylamine (0.99 mL, 7.1 mmol) at room temperature is added slowly 2-mercapto-3-(trifluoromethyl)pyridine (2.29 g, 12.8 mmol). The reaction is stirred overnight at room temperature. The resulting mixture is diluted with water and the mixture is then extracted with ethyl acetate (3 x 50 mL). The combined ethyl acetate layer is washed with brine, dried of
15 MgSO₄, filtered and concentrated to an oil under reduced pressure. Purification is done by column chromatography with 30% ethyl acetate in hexanes to 40% ethyl acetate in hexanes as the eluent to give the desired product.

b. **2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(3-trifluoromethyl)-2-pyridyl-thio]-pentanoic acid:** To a solution of 3-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-2-oxo-5-[(3-trifluoromethyl)-2-pyridyl-thio]methyl-tetrahydrofuran **61a** (1.67 g, 3.1 mmol) in water (5 mL) and THF (5 mL) is slowly added lithium hydroxide (0.74 g, 31 mmol). The reaction is stirred for 4 hr, then concentrated to dryness. The reaction mixture is diluted with water and then the mixture is extracted with ethyl ether (2 x 25 mL). The ethyl ether layer is discarded and the aqueous layer is slowly acidified with 1N HCl to
25 pH 5, and then extracted 3 times with ethyl acetate. The combined ethyl acetate layers are washed with water and brine, dried over MgSO₄, filtered and concentrated under reduced pressure. The compound is purified by HPLC to give the desired product as a white solid.
30

Example 62

35 **2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]-N-methyl-amino-4-hydroxy-5-(phenylthio)-pentanoic acid**

-59-



5

a. **Methyl 2-[(4'-methoxy[1,1'-biphenyl]-4-yl)-N-methylamino-4-penteneoate:** To a stirred solution of methyl 2-[(4'-methoxy[1,1'-biphenyl]-4-yl)amino-4-penteneoate **1c** (3.6 g, 9.6 mmol) in DMF (75 mL) is added Na bis(TMS)amide (1.0 M, 12 mL) followed by methyl iodide (2.04 g, 14.4 mmol) and this mixture is stirred overnight at room temperature. 1 N HCl (25 mL) is then added and the mixture is diluted with water and is extracted with ethyl acetate (3 x 100 mL). The combined ethyl acetate layer is washed with brine, dried with MgSO₄, filtered and concentrated under reduced pressure to the crude product. The crude is purified by column chromatography eluting with 30% ethyl acetate in hexanes to get the desired product.

b. **Methyl N-methyl-2-[(4'-methoxy[1,1'-biphenyl]-4-yl)-amino-4,5-epoxypentanoate:** To a solution of methyl 2-[(4'-methoxy[1,1'-biphenyl]-4-yl)amino-4-penteneoate **62a** (1.64 g, 4.2 mmol) in CH₂Cl₂ (30 mL), NaHCO₃ (0.42 g, 5.1 mmol) and water (15 mL) at 0° C, is slowly added m-chloroperbenzoic acid (57-86%) (1.5 g, ~9 mmol). The reaction is stirred for 18 hr. The mixture is diluted with aqueous NaHCO₃ and this mixture is extracted with ethyl acetate (3 x 250 mL). The combined ethyl acetate layer is washed with brine, dried over MgSO₄, filtered and concentrated to an oil. Purification of this compound is accomplished by column chromatography with 40% ethyl acetate in hexanes as the eluent to give the desired product.

c. **N-Methyl 3-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-2-oxo-5-[(2-benzothiazolyl)thio]methyl]-tetrahydrofuran:** To a solution of methyl 2-[(4'-methoxy[1,1'-biphenyl]-4-yl)amino-4,5-epoxypentanoate **62b** (1.07 g, 2.65 mmol) in benzene (10 mL) and triethylamine (0.52 mL, 3.7 mmol) at room temperature is added slowly 2-mercaptothiazole (0.78 g, 6.6 mmol). The reaction is stirred overnight at room temperature. The resulting mixture is diluted with water and the mixture is then extracted with ethyl acetate (3 x 25 mL). The combined ethyl acetate layer is washed with brine, dried of MgSO₄, filtered and concentrated to an oil under reduced pressure. Purification is done by column chromatography with 30% ethyl acetate in hexanes to 40% ethyl acetate in hexanes as the eluent to give the desired product.


30

- 5 d. ***N*-Methyl 2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-benzothiazolylthio]-pentanoic acid:** To a solution of *N*-methyl 3-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-2-oxo-5-[[2-benzothiazolylthio]methyl]-tetrahydrofuran **62c** (1.00 g, 2.05 mmol) in water (5 mL) and THF (5 mL) is slowly added lithium hydroxide (0.49 g, 20.5 mmol). The reaction is stirred for 4 hr, then concentrated to dryness. The reaction mixture is diluted with
 10 water and then the mixture is extracted with ethyl ether (2 x 25 mL). The ethyl ether layer is discarded and the aqueous layer is slowly acidified with 1N HCl to pH 5, and then extracted 3 times with ethyl acetate. The combined ethyl acetate layers are washed with water and brine, dried over MgSO₄, filtered and concentrated under reduced pressure. The white solid is then recrystallized with ethyl acetate/ hexanes to give the desired product as a white solid.


15

Examples 63-67

The following chemical formula along with Table 2 shows the structure of compounds made according to the description in Examples 63-67 described below.

Table 2

Example	R ₁	R ₂	R ₃
63			
64			
65			-H
66			

**Example 63**

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-3-phenylmethoxy-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid

a. **N-[(1,1-Dimethylethoxy)carbonyl]glycine-4-phenylmethoxy-2-butenyl ester:** N-[(1,1-Dimethylethoxy)carbonyl]glycine (21.9 grams, 0.125 mol), cis-4-benzyloxy-2-buten-1-ol (25 mL, 0.15 mol), and 4-dimethylaminopyridine (1.5 grams, 0.013 mol) are dissolved in methylene chloride and stirred at 0°C. Then N,N-dicyclohexylcarbodiimide (31 grams, 0.15 mol) in 30 mL methylene chloride is added and the reaction is stirred at 0°C for five minutes. The reaction is then stirred for an additional twelve hours at 25°C. Additional methylene chloride is added and the reaction is washed consecutively with 1 N HCl, sodium bicarbonate and then with brine. The organic extract is dried over magnesium sulfate and the solvent evaporated *in vacuo* to give an orange oil which is absorbed onto silica gel and applied to a dry silica column. The column is eluted with hexane/EtOAc (9:1) then with hexane/EtOAc (8:2). Product fractions are combined and dried *in vacuo* to give the desired product.

b. **2-[(1,1-Dimethylethoxy)carbonyl]amino-3-phenylmethoxy-4-pentenoic acid:** A lithium diisopropylamide solution (37.3 M) is prepared from N,N-diisopropylamine (5.2 mL, 37.2 mmol) in THF (30 mL, cooled to -20°C) and 3.7 mL (37.3 mmol) 10 M *n*-BuLi in hexane. The LDA solution in THF is added to a stirred solution of N-[(1,1-dimethylethoxy)carbonyl]glycine-4-phenylmethoxy-2-butenyl ester **63a** (14.9 mmol) and ZnCl₂ (17.9 mmol) in 100 mL THF at -78°C. The mixture is allowed to come to room temperature overnight. The crude mixture is partitioned between 700 mL ethyl acetate and 700 mL 1 N HCl. The organic layer is washed with 150 mL dilute NaHCO₃ solution (3x's). The bicarbonate washes are acidified with conc. HCl to pH1 and extracted with 700 mL ethyl acetate. The ethyl acetate layer is dried over magnesium sulfate and the solvent removed *in vacuo* to give the named compound.

c. **Methyl 2-[4-bromophenylsulfonyl]amino-3-phenylmethoxy-4-pentenoate:** The 2-[(1,1-dimethylethoxy)carbonyl]amino-3-phenylmethoxy-4-pentenoic acid **63b** (1.8 g, 5.37 mmol) is dissolved in methanol (54 mL) and thionyl chloride (8.3 mL) is added dropwise to the mixture. The resulting mixture is stirred at room temperature until the reaction is complete by tlc. The crude reaction is dried and re-evaporated from methanol (3 times). The dried reaction mixture is

5 taken up in methylene chloride (30 mL) and triethylamine (7 mL). 4-Bromophenylsulfonyl chloride (1.23 g, 4.83 mmol) is added and the reaction is stirred overnight. The solvent is removed *in vacuo* and the oil is taken up in ethyl acetate, and then washed consecutively with 1N HCl, saturated sodium bicarbonate solution, and finally with brine, then dried over magnesium sulfate and the solvent removed *in vacuo*. The crude material is adsorbed onto silica gel and
10 purified over a silica column eluting with hexane followed with hexane:ethyl acetate (8:2). Product fractions are combined and dried to give the desired product.

d. Methyl 2-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-3-phenylmethoxy-4-pentenoate: The methyl 2-[4-bromophenylsulfonyl]amino-3-phenylmethoxy-4-pentenoate **63c** (320 mg, 0.683 mmol) is dissolved in benzene (4 mL) and sodium carbonate (148 mg), in water
15 (0.6 mL), is added along with tetrakis(triphenylphosphine)palladium. 4-Methoxyphenylboronic acid (157 mg, 1.03 mmol), in methanol (0.4 mL), is added and the mixture is heat to reflux overnight. Ether is added to the reaction which is washed with water (3 times) and brine, the organic layer is dried over magnesium sulfate and the solvent stripped *in vacuo* to give the crude product as a yellow solid. The crude material is adsorbed onto silica gel and purified over a
20 silica column eluting with hexane/ethyl acetate (9:1) followed with hexane/ethyl acetate (1/1). Product fractions are combined and dried to give the desired product.

e. Methyl 2-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-3-phenylmethoxy-4,5-epoxypentanoate: The methyl 2-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-3-phenylmethoxy-4-pentenoate **63d** (1.23 g, 2.48 mmol) is dissolved in methylene chloride (9 mL)
25 and sodium bicarbonate (252 mg), in water (4 mL), then the reaction is cooled to 0°C. 3-Chloroperoxybenzoic acid is added slowly and the reaction is stirred for two hours. The substrate is still present so additional 3-chloroperoxybenzoic acid is added (1 g) along with 175 mg sodium bicarbonate and the reaction is stirred overnight. The mixture is diluted with aqueous sodium bicarbonate solution and methylene chloride and the layers are separated. The aqueous
30 layer is washed with ethyl acetate (3 times) and the organic layers are combined and dried under reduced pressure. The resulting material is redissolved in ethyl acetate and washed with dilute sodium bicarbonate solution and then with brine, dried over magnesium sulfate and concentrated *in vacuo* to a light brown oil (2 g). The crude material is adsorbed onto silica gel and purified over a silica column eluting with hexane:ethyl acetate (8:2) followed with hexane:ethyl acetate (1:1). Product fractions are combined and dried to give the desired product.

f. 3-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-2-oxo-4-phenylmethoxy-5-[(2-thiazolyl)thio]methyl]-tetrahydrofuran: The methyl 2-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-3-phenylmethoxy-4,5-epoxypentanoate **63e** (285 mg, 0.558 mmol) is dissolved in benzene/triethylamine (2.5 mL, 0.101 mmol) and 2-mercaptothiazole (164 mg, 1.40

-63-

5 mmol) is added. The resulting mixture is then stirred at room temperature for four hours. The mixture is diluted with ethyl acetate and water and extracted with ethyl acetate (3 times). The organic layer is washed with water and brine, then dried over magnesium sulfate and concentrated to a clear oil.. The crude material is adsorbed onto silica and purified over a silica column eluting with ethyl acetate/hexane (2/8) followed with ethyl acetate/hexane (1/1). Product
10 fractions are combined and the solvent is removed *in vacuo* to give the desired product as a clear oil.

g. **2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-3-phenylmethoxy-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid:** The 3-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-2-oxo-4-phenylmethoxy-5-[[2-thiazolyl)thio]methyl]-tetrahydrofuran 63f, 154 mg, 0.258 mmol) is
15 dissolved in THF/water (2 mL/2 mL) and lithium hydroxide (108 mg, 2.58 mmol) is added and the reaction is stirred for two hours at room temperature. The reaction is concentrated to remove the solvent, diluted with water and extracted (2 times) with ether. The aqueous layer is neutralized with 1N HCl to pH6 and extracted with ethyl acetate (3 times). The combined organic layer is washed with brine, dried over magnesium sulfate, and the solvent removed *in*
20 *vacuo*. The crude material is adsorbed onto silica gel and purified over a short silica column eluting with hexane/ethyl acetate (1/1) followed with ethyl acetate and ethyl acetate/methanol (8/2). Product fractions are combined and dried to give the desired product as a white solid.

Example 64

25 **2-[(4'-Thiomethoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-3-phenylmethoxy-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid**

Example 64 is prepared from 4-(methylthio)phenylboronic acid and 63d using the procedure described for compound 63.

Example 65

30 **2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-3,4-dihydroxy-5-[(2-thiazolyl)thio]-pentanoic acid**

Example 65 is prepared from compound 63g by hydrogenolysis of the corresponding benzyl ether.

Example 66

35 **2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-3,4-dihydroxy-5-[(4-methyl-4(H)-1,2,4-triazol-3-yl)thio]-pentanoic acid**

- 5 Example 66 is prepared from compound 63e and 4-methyl-4H-1,2,4-triazole-3-thiol using the procedure described for compound 63.

Example 67

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-3,4-dihydroxy-5-[(4-methyl-4(H)-1,2,4-triazol-3-yl)thio]-pentanoic acid

- 10 Example 67 is prepared from compound 66 by hydrogenolysis of the corresponding benzyl ether.

Examples 68-72

The following chemical formula along with Table 3 shows the structure of compounds made according to the description in Examples 68-72 described below.














Table 3

Example	R ₁	X	R ₃
68		-O-	
69		-O-	
70		-O-	
71		-O-	
72		-S-	

Example 68

2-[(4'-Methoxy-[1,1'-biphenyl]-4-yl)-sulfonyl]-amino-3-(2-phenoxyethyl-[1,3]dioxan-2-yl)-propionic acid

- 10 a. **Ethyl 2-*tert*-butoxycarbonylamino-4-oxo-5-bromopentanoate:** The starting ethyl 2-*tert*-butoxycarbonylamino-4-bromopent-4-enoate (1.6 g, 4.57 mmol; *Tetrahedron* 1997, 33, 88; *Tetrahedron Lett* 1994, 3669) is taken in CH₃CN:H₂O (4:1), treated with *N*-bromosuccinamide (1.06 g, 5.94 mmol) and five drops of 48% HBr and stirred for 3 hr. The mixture is then partitioned between dil. NaHCO₃ and hexanes:EtOAc (1:1). The organic layer is washed with
- 15 brine, dried over MgSO₄, filtered and evaporated. The residue is purified over flash silica with hexanes:EtOAc (10:1 to 7:3) to give a pale yellow oil which solidified upon standing.
- b. **Ethyl 2-*tert*-butoxycarbonylamino-4-oxo-5-phenoxy-pentanoate:** The starting bromoketone 68a (3 g, 8.9 mmol) is taken in 80 mL of THF:DMF (5:3) in the presence of phenol (1.0g, 10.7 mmol) and 4.7 g of Na₂CO₃. The resulting solution is heated to 85°C for 16 hr,
- 20 cooled to RT, diluted with EtOAc, washed with water and then dil. Na₂CO₃, dried over MgSO₄, filtered and evaporated to give a tan oil which is purified over flash silica with hexanes:EtOAc (3:1) to yield a pale yellow oil.
- c. **Ethyl 2-amino-3-(2-phenoxyethyl-[1,3]dioxan-2-yl)-propionate:** The starting ketone 68b (2.14 g, 6.3 mmol) is taken in 20 mL of methylene chloride in the presence of 1,3-

5 dihydroxypropane (2.95 g, 13.4 mmol) and treated with boron trifluoroetherate (2.4 mL, 19.1 mmol). The resulting mixture is allowed to stir for 2 hr, diluted with EtOAc, washed with 1N NaOH, washed with 5% NH₄Cl, dried over MgSO₄, filtered and evaporated to give a pale yellow oil.

d. Ethyl 2-[(4'-Methoxy-[1,1'-biphenyl]-4-yl)-sulfonyl]-amino-3-(2-phenoxyethyl-
10 [1,3]dioxan-2-yl)-propionate: The free amine 68c (982 mg, 3.17 mmol) is taken in 20 mL of CH₂Cl₂ in the presence of 2 mL of NEt₃, treated with (4'-methoxy-[1,1'-biphenyl]-4-yl)-sulfonyl chloride (1.07 g, 3.81 mmol), stirred for 12 hr and partitioned between EtOAc and 1N HCl. The organic layer is washed with brine, dried over MgSO₄, filtered and evaporated to give a yellow solid which is purified over flash silica with hexanes:EtOAc (3:2) to give a white solid.

15 e. The starting ester 68d is hydrolyzed as described for compound 1f to give the title acid as a white solid.

Example 69

2-[(4'-Bromo-[1,1'-biphenyl]-4-yl)-sulfonyl]-amino-3-(2-phenoxyethyl-
propionic acid

20 The starting free amine 68c is coupled to (4'-Bromo-[1,1'-biphenyl]-4-yl)-sulfonyl chloride and carried forward to the title acid as described for compounds 68c-e.

Example 70

2-[(4'-Methoxy-[1,1'-biphenyl]-4-yl)-sulfonyl]-amino-3-(2-thiophenoxyethyl-
2-yl)-propionic acid

25 The bromoketone 68a is coupled with thiophenol and carried forward to the title acid as described for compounds 68b-e.

Example 71

2-[(4'-Methoxy-[1,1'-biphenyl]-4-yl)-sulfonyl]-amino-3-[2-(2-oxo-azepan-1-ylmethyl)-
[1,3]dioxan-2-yl]-propionic acid

30 a. Ethyl 2-*tert*-butoxycarbonylamino-4-oxo-5-phenoxy-pentanoate: The starting bromoketone 68a (1.0 g, 3.0 mmol) is dissolved in 1 mL of DMF, treated with 1-aza-2-methoxy-1-cycloheptene (0.518 mL, 3.6 mmol) and heated to 60 °C for 16 hr. The mixture is then dissolved in EtOAc, washed three times with water, dried over Na₂SO₄, filtered and evaporated to give an amber oil. This material is then purified over flash silica with hexanes:EtOAc (4:6) to
35 give the desired lactam as a yellow oil.

b. The starting lactam 71a is carried forward to the title acid as described for compounds 68c-e.

Example 72

5 **2-[(4'-Methoxy-[1,1'-biphenyl]-4-yl)-sulfonyl]-amino-3-(2-phenoxyethyl-[1,3]dioxan-2-yl)-propionic acid**

The starting ketone 68c is ketalized with 1,3-propanethiol and carried forward to the title acid as described for compound 68c-d.

IX. Examples - Compositions and Methods of Use

10 The compounds of the invention are useful to prepare compositions for the treatment of ailments associated with unwanted MP activity. The following composition and method examples do not limit the invention, but provide guidance to the skilled artisan to prepare and use the compounds, compositions and methods of the invention. In each case other compounds within the invention may be substituted for the example compound shown below with similar
15 results. The skilled practitioner will appreciate that the examples provide guidance and may be varied based on the condition being treated and the patient.

The following abbreviations are used in this section:

EDTA: ethylenediaminetetracetic acid

SDA: synthetically denatured alcohol

20 USP: United States Pharmacopoeia

Example A

A tablet composition for oral administration, according to the present invention, is made comprising:

	<u>Component</u>	<u>Amount</u>
25	The compound of Example 1	15 mg
	Lactose	120 mg
	Maize Starch	70 mg
	Talc	4 mg
	Magnesium Stuart	1 mg

30 A human female subject weighing 60 kg (132 lbs), suffering from rheumatoid arthritis, is treated by a method of this invention. Specifically, for 2 years, a regimen of three tablets per day is administered orally to said subject.

At the end of the treatment period, the patient is examined and is found to have reduced inflammation, and improved mobility without concomitant pain.

35 Example B

A capsule for oral administration, according to the present invention, is made comprising:

-68-

5	<u>Component</u>	<u>Amount (%w/w)</u>
	The compound of Example 6	15%
	Polyethylene glycol	85%

A human male subject weighing 90 kg (198 lbs.), suffering from osteoarthritis, is treated by a method of this invention. Specifically, for 5 years, a capsule containing 70 mg of the compound of Example 3 is administered daily to said subject.

At the end of the treatment period, the patient is examined via x-ray, arthroscopy and/or MRI, and found to have no further advancement of erosion/fibrillation of the articular cartilage.

Example C

A saline-based composition for local administration, according to the present invention, is made comprising:

	<u>Component</u>	<u>Amount (%w/w)</u>
	The compound of Example 10	5 %
	Polyvinyl alcohol	15%
	Saline	80%

A patient having deep corneal abrasion applies the drop to each eye twice a day. Healing is speeded, with no visual sequelae.

Example D

A topical composition for local administration, according to the present invention, is made comprising:

25	<u>Component</u>	<u>Composition (% w/v)</u>
	The compound of Example 19	0.20
	Benzalkonium chloride	0.02
	Thimerosal	0.002
	d-Sorbitol	5.00
30	Glycine	0.35
	Aromatics	0.075
	<u>Purified water</u>	<u>q.s.</u>
	Total =	100.00

A patient suffering from chemical burns applies the composition at each dressing change (b.i.d.). Scarring is substantially diminished.

Example E

5 An inhalation aerosol composition, according to the present invention, is made comprising:

	<u>Component</u>	<u>Composition (% w/v)</u>
	Compound of Example 42	5.0
	Alcohol	33.0
10	Ascorbic acid	0.1
	Menthol	0.1
	Sodium Saccharin	0.2
	<u>Propellant (F12, F114)</u>	<u>q.s.</u>
	Total =	100.0

15 An asthma sufferer sprays 0.01 mL via a pump actuator into the mouth while inhaling. Asthma symptoms are diminished.

Example F

A topical ophthalmic composition, according to the present invention, is made comprising:

	<u>Component</u>	<u>Composition (% w/v)</u>
20	Compound of Example 54	0.10
	Benzalkonium chloride	0.01
	EDTA	0.05
	Hydroxyethylcellulose (NATROSOL M)	0.50
25	Sodium metabisulfite	0.10
	<u>Sodium chloride (0.9%)</u>	<u>q.s.</u>
	Total =	100.0

A human male subject weighing 90 kg (198 lbs), suffering from corneal ulcerations, is treated by a method of this invention. Specifically, for 2 months, a saline solution containing 10
30 mg of the compound of Example 54 is administered to said subject's affected eye twice-daily.

Example G

A composition for parenteral administration is made comprising:

	<u>Component</u>	<u>Amount</u>
	The compound of Example 22	100 mg/mL carrier
35	<u>Carrier:</u>	
	Sodium citrate buffer with (percent by weight of carrier):	

-70-

5	lecithin	0.48%
	carboxymethylcellulose	0.53
	povidone	0.50
	methyl paraben	0.11
	propyl paraben	0.011

10 The above ingredients are mixed, forming a suspension. Approximately 2.0 mL of the suspension is administered, via injection, to a human subject with a premetastatic tumor. The injection site juxtaposes the tumor. This dosage is repeated twice daily, for approximately 30 days. After 30 days, symptoms of the disease subside, and dosage is gradually decreased to maintain the patient.

15 Example H

A mouthwash composition is prepared:

	<u>Component</u>	<u>%w/v</u>
	The compound of Example 51	3.00
	SDA 40 Alcohol	8.00
20	Flavor	0.08
	Emulsifier	0.08
	Sodium Fluoride	0.05
	Glycerin	10.00
	Sweetener	0.02
25	Benzoic acid	0.05
	Sodium hydroxide	0.20
	Dye	0.04
	Water	balance to 100%

A patient with gum disease uses 1 mL of the mouthwash thrice daily to prevent further
30 oral degeneration.

-71-

5

Example I

A lozenge composition is prepared:

	<u>Component</u>	<u>%w/v</u>
	The compound of Example 11	0.01
	Sorbitol	17.50
10	Mannitol	17.50
	Starch	13.60
	Sweetener	1.20
	Flavor	11.70
	Color	0.10
15	Corn Syrup	balance to 100%

A patient uses the lozenge to prevent loosening of an implant in the maxilla.

Example J

Chewing Gum Composition

	<u>Component</u>	<u>w/v%</u>
20	The compound of Example 9	0.03
	Sorbitol crystals	38.44
	Paloja-T gum base	20.00
	Sorbitol (70% aqueous solution)	22.00
	Mannitol	10.00
25	Glycerine	7.56
	Flavor	1.00

A patient chews the gum to prevent loosening of dentures.

Example K

	<u>Components</u>	<u>w/v%</u>
30	Compound of Example 37	4.0
	USP Water	50.656
	Methylparaben	0.05
	Propylparaben	0.01
	Xanthan Gum	0.12
35	Guar Gum	0.09
	Calcium carbonate	12.38
	Antifoam	1.27

-72-

5	Sucrose	15.0
	Sorbitol	11.0
	Glycerin	5.0
	Benzyl Alcohol	0.2
	Citric Acid	0.15
10	Coolant	0.00888
	Flavor	0.0645
	Colorant	0.0014

The composition is prepared by first mixing 80 kg of glycerin and all of the benzyl alcohol and heating to 65°C, then slowly adding and mixing together methylparaben, propylparaben, water, xanthan gum, and guar gum. Mix these ingredients for about 12 minutes with a Silverson in-line mixer. Then slowly add in the following ingredients in the following order: remaining glycerin, sorbitol, antifoam C, calcium carbonate, citric acid, and sucrose. Separately combine flavors and coolants and then slowly add to the other ingredients. Mix for about 40 minutes. The patient takes the formulation to prevent flare up of colitis.

20 Example L

An obese human female subject, who is determined to be prone to osteoarthritis, is administered the capsule described in Example B to prevent the symptoms of osteoarthritis. Specifically, a capsule is administered daily to the subject.

The patient is examined via x-ray, arthroscopy and/or MRI, and found to have no significant advancement of erosion/fibrillation of the articular cartilage.

Example M

A human male subject weighing 90 kg (198 lbs.), who suffers a sports injury to the knee, is administered the capsule described in Example B to prevent the symptoms of osteoarthritis. Specifically, a capsule is administered daily to the subject.


30 The patient is examined via x-ray, arthroscopy and/or MRI, and found to have no significant advancement of erosion/fibrillation of the articular cartilage.

All references described herein are hereby incorporated by reference.

While particular embodiments of the subject invention have been described, it will be obvious to those skilled in the art that various changes and modifications of the subject invention can be made without departing from the spirit and scope of the invention. It is intended to cover, in the appended claims, all such modifications that are within the scope of this invention.

What is claimed is:

1. A compound having a structure according to Formula (I)



(I)

characterized in that


- (A) X is selected from -OH and -NHOH; or when J is $-D-(CR^{14}R^{14'})R^{15}$ where D is -O-, as defined below, X can optionally be a covalent bond which joins with J to form a 5 to 9 membered ring;
- (B) W is selected from -S-, -O-, $-N(R^{32})-$, $-C(R^{32})=C(R^{32})-$, $-N=C(R^{32})-$, and $-N=N-$, where R^{32} and $R^{32'}$ each is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
- (C) R^1 is selected from hydrogen, hydroxyl, alkoxy, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, and halogen;
- (D) R^2 is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, and heterocycloalkyl;
- (E) T is $-(CR^8R^8')_p-A-(CR^{8''}R^{8'''})_qR^9$ where
 - (1) p is from 0 to about 4;
 - (2) q is from 0 to about 4;
 - (3) each R^8 , R^8' , $R^{8''}$, and $R^{8'''}$ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and haloalkyl;
 - (4) R^9 is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and halogen; and

- (5) A is selected from a covalent bond; -O-; -SO_r- where *r* is 0, 1 or 2; and -NR¹⁰- where R¹⁰ is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, or R¹⁰ can join with R⁹ to form a ring with 5 to 8 members and 1 to 3 heteroatoms; provided that when *p* is 0, A is a covalent bond;
- (F) R³ is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and;
- (G) each R⁴ and R^{4'} is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, and alkoxy; and *n* is from 0 to about 4;
- (H) R⁵ is -(CR¹¹R^{11'})_sR¹² where
- (1) *s* is from 0 to about 4;
 - (2) each R¹¹ and R^{11'} is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and haloalkyl; and
 - (3) R¹² is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halogen, and GR¹³ where G is -O- or -S- and R¹³ is selected from hydrogen, alkyl, and aryl;
- (I) J is -D-(CR¹⁴R^{14'})_tR¹⁵ where
- (1) *t* is from 0 to about 4;
 - (2) D is selected from -O-; -SO_u- where *u* is from 0 to 2; and -NR¹⁶- where R¹⁶ is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, or R¹⁶ can join with R¹⁵ to form a ring with 5 to 8 members and 1 to 3 heteroatoms;
 - (3) each R¹⁴ and R^{14'} is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and haloalkyl; and
 - (4) R¹⁵ is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, and; or R¹⁵ can join with R¹³ to form an optionally substituted ring with 5 to 9 ring members of which from 2 to 3 are heteroatoms;
- (J) each R⁶ and R^{6'} is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, and alkoxy; and *m* is from 0 to about;

- (K) R^7 is $-(CR^{17}R^{17'})_vR^{18}$ where
- (1) v is from 0 to about 4;
 - (2) R^{17} and $R^{17'}$ are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and haloalkyl; and
 - (3) R^{18} is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and halogen;
- (L) M is $-E-(CR^{19}R^{19'})_wR^{20}$ where
- (1) w is from 0 to about 4;
 - (2) E is selected from a $-O-$; $-SO_x-$ where x is from 0 to 2; and $-NR^{21}-$ where R^{21} is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, or R^{21} can join with R^{20} to form a ring with 5 to 8 members and 1 to 3 heteroatoms;
 - (3) each R^{19} and $R^{19'}$ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and haloalkyl; and
 - (4) R^{20} is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
- (M) Q is $-G'-(CR^{22}R^{22'})_yR^{23}$ where
- (1) y is from 0 to about 4;
 - (2) G' is selected from a covalent bond; $-O-$; $-SO_z-$ where z is from 0 to 2; and $-NR^{24}-$ where R^{24} is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, or R^{24} can join with R^{22} to form an optionally substituted ring with 5 to 8 ring members of which from 1 to 3 are heteroatoms;
 - (3) each R^{22} and $R^{22'}$ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and haloalkyl;
 - (4) R^{23} is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, and, or R^{23} can join with R^{20} to form a ring from 5 to 8 members with 1 to 3 heteroatoms; and
- (N) Z is selected from
- (1) cycloalkyl and heterocycloalkyl;
 - (2) $-D'-(CR^{25}R^{25'})_oR^{26}$ where

- (a) a is from 0 to about 4;
 - (b) when a is from 0 to about 4 then D' is selected from $-C\equiv C-$, $-CH=CH-$, $-O-$, and $-S-$, and when a is from 1 to about 4, then D is selected from $-C\equiv C-$, $-CH=CH-$, $-N=N-$, $-O-$, $-S-$ and $-SO_2-$;
 - (c) each R^{25} and $R^{25'}$ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, and alkoxy; and
 - (d) R^{26} is selected from hydrogen, aryl, heteroaryl, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, heterocycloalkyl and cycloalkyl; and, if D' is $-C\equiv C-$ or $-CH=CH-$, then R^{26} may also be selected from $-CONR^{27}R^{27'}$ where (i) R^{27} and $R^{27'}$ are independently selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, or (ii) R^{27} and $R^{27'}$, together with the nitrogen atom to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 ring atoms of which from 1 to 3 are heteroatoms;
- (3) $-NR^{28}R^{28'}$ where
- (a) R^{28} and $R^{28'}$ each is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heteroalkyl and $-C(O)-Q'-(CR^{29}R^{29'})_bR^{30}$ where
 - (i) b is from 0 to about 4;
 - (ii) Q' is selected from a covalent bond and $-NR^{31}-$; and
 - (iii) each R^{29} and $R^{29'}$ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, and alkoxy; R^{30} and R^{31} (i) each is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, or (ii) R^{30} and R^{31} , together with the atoms to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 ring atoms of which from 1 to 3 are heteroatoms; or R^{28} and R^{31} , together with the nitrogen atoms to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 ring atoms of which from 2 to 3 are heteroatoms; or

- (c) R^{28} and $R^{28'}$, together with the nitrogen atom to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 ring atoms of which from 1 to 3 are heteroatoms; and




- (a) E' and Y are independently selected from $-CH-$ and $-N-$;
 (b) L is selected from $-S-$, $-O-$, $-N(R^{35})-$, $-C(R^{35})=C(R^{35'})-$, $N=C(R^{35})-$, and $-N=N-$, where R^{35} and $R^{35'}$ each is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
 (c) c is from 0 to about 4;
 (d) each R^{33} and $R^{33'}$ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, and alkoxy;
 (e) A' is selected from covalent bond, $-O-$, $-SO_d-$, $-C(O)-$, $C(O)NR^{36}-$, $-NR^{36}-$, and $-NR^{36}C(O)-$; where d is from 0 to 2 and R^{36} is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, haloalkyl; and
 (f) T' is $-(CR^{37}R^{37'})_e-R^{38}$ where e is from 0 to about 4; each R^{37} and $R^{37'}$ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, alkoxy and aryloxy; and R^{38} is selected from hydrogen, alkyl, alkenyl, alkynyl, halogen, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; or R^{35} and R^{38} , together with the atoms to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 atoms of which 1 to 3 are heteroatoms; or R^{35} and R^{38} , together with the atoms to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 atoms of which 1 to 3 are heteroatoms;

or an optical isomer, diastereomer or enantiomer for Formula (I), or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof.

2. A compound having a structure according to Formula (II)

78



(II)


characterized in that

- (A) W is selected from -S-, -O-, -N(R³²)-, -C(R³²)=C(R^{32'})-, -N=C(R³²)-, and N=N-, where R³² and R^{32'} each is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
- (B) J is -D-(CR¹⁴R^{14'})_tR¹⁵ where
- (1) *t* is from 0 to about 4;
 - (2) D is selected from -O-, -SO_u- where *u* is from 0 to 2; and -NR¹⁶- where R¹⁶ is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, or R¹⁶ can join with R¹⁵ to form a ring with 5 to 8 members and 1 to 3 heteroatoms;
 - (3) each R¹⁴ and R^{14'} is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and haloalkyl; and
 - (4) R¹⁵ is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, and; or R¹⁵ can join with R¹³ to form a ring with 5 to 9 members and contain from 2 to 3 heteroatoms;
- (C) M is -E-(CR¹⁹R^{19'})_wR²⁰ where
- (1) *w* is from 0 to about 4;
 - (2) E is selected from a -O-, -SO_x- where *x* is from 0 to 2; and -NR²¹- where R²¹ is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, or R²¹ can join with R²⁰ to form a ring with 5 to 8 members and 1 to 3 heteroatoms;
 - (3) each R¹⁹ and R^{19'} is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, and haloalkyl;

- (4) R^{20} is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; and
- (D) Z is selected from
- (1) cycloalkyl and heterocycloalkyl;
 - (2) $-D'-(CR^{25}R^{25'})_aR^{26}$ where
 - (a) a is from 0 to about 4;
 - (b) when a is from 0 to about 4 then D' is selected from $-C\equiv C-$, $-CH=CH-$, $-O-$, and $-S-$, and when a is from 1 to about 4, then D is selected from $-C\equiv C-$, $-CH=CH-$, $-N=N-$, $-O-$, $-S-$ and $-SO_2-$;
 - (c) each R^{25} and $R^{25'}$ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, and alkoxy; and
 - (d) R^{26} is selected from hydrogen, aryl, heteroaryl, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, heterocycloalkyl and cycloalkyl; and, if D' is $-C\equiv C-$ or $-CH=CH-$, then R^{26} may also be selected from $-CONR^{27}R^{27'}$ where (i) R^{27} and $R^{27'}$ are independently selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, or (ii) R^{27} and $R^{27'}$, together with the nitrogen atom to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 ring atoms of which from 1 to 3 are heteroatoms;
 - (3) $-NR^{28}R^{28'}$ where
 - (a) R^{28} and $R^{28'}$ each is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, heteroalkyl and $-C(O)-Q'-(CR^{29}R^{29'})_bR^{30}$ where
 - (i) b is from 0 to about 4;
 - (ii) Q' is selected from a covalent bond and $-NR^{31}-$; and
 - (iii) each R^{29} and $R^{29'}$ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, and alkoxy; R^{30} and R^{31} (i) each is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, or (ii) R^{30} and R^{31} , together with the atoms to which they are bonded, join to form an optionally

substituted heterocyclic ring containing from 5 to 8 ring atoms of which from 1 to 3 are heteroatoms; or R^{28} and R^{31} , together with the nitrogen atoms to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 ring atoms of which from 1 to 3 are heteroatoms; or

- (b) R^{28} and $R^{28'}$, together with the nitrogen atom to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 ring atoms of which from 1 to 3 are heteroatoms; and




- (a) E' and Y are independently selected from $-CH-$ and $-N-$;
- (b) L is selected from $-S-$, $-O-$, $-N(R^{35})-$, $-C(R^{35})=C(R^{35'})-$, $-N=C(R^{35})-$, and $-N=N-$, where R^{35} and $R^{35'}$ each is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
- (c) c is from 0 to about 4;
- (d) each R^{33} and $R^{33'}$ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, and alkoxy;
- (e) A' is selected from covalent bond, $-O-$, $-SO_d-$, $-C(O)-$, $-C(O)NR^{36}-$, $-NR^{36}-$, and $-NR^{36}C(O)-$; where d is from 0 to 2 and R^{36} is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, haloalkyl; and
- (f) T' is $-(CR^{37}R^{37'})_e-R^{38}$ where e is from 0 to about 4; each R^{37} and $R^{37'}$ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, heterocycloalkyl, halogen, haloalkyl, hydroxy, alkoxy and aryloxy; and R^{38} is selected from hydrogen, alkyl, alkenyl, alkynyl, halogen, heteroalkyl, haloalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; or R^{35} and R^{38} , together with the atoms to which they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 atoms of which 1 to 3 are heteroatoms; or R^{35} and R^{38} , together with the atoms to which

they are bonded, join to form an optionally substituted heterocyclic ring containing from 5 to 8 atoms of which 1 to 3 are heteroatoms; or an optical isomer, diastereomer or enantiomer for Formula (I), or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof.

3. A compound of Claim 1 or 2, characterized in that W is selected from -S- and -CH=CH-.

4. A compound of any of Claims 1-3 characterized in that Z is selected from -D'-



5. A compound of Claim 4 characterized in that:

(a) when Z is -D'-(CR²⁵R^{25'})_aR²⁶, D' is selected from -C≡C-, -C=C- and -N=N-; a is 0; and R²⁶ is selected from aryl, heteroaryl, heterocycloalkyl and cycloalkyl;

(b) when Z is -NR²⁸R^{28'}, R²⁸ is hydrogen and R^{28'} is -C(O)-Q'-(CR²⁹R^{29'})_bR³⁰ where Q' is a covalent bond and b is 0, where R³⁰ is preferably selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; and

(c) when Z is $\begin{array}{c} E'-Y \\ \diagup \quad \diagdown \\ \text{---} \quad L \quad \text{---} \\ \diagdown \quad \diagup \end{array} (CR^{33}R^{33'})_c A'-T$, E' and Y are both -CH-, c is 0, L is -C(R³⁵)=C(R³⁵)- (L is preferably -HC=CH-) and R³⁵ and T' join to form an optionally substituted 5-membered ring containing from 0 to 2 ring heteroatoms.

6. A compound of any of Claims 1-5 characterized in that A' is selected from a covalent bond, -O- and -S-; and T' is -(CR³⁷R^{37'})_e-R³⁸ where e is 0 and R³⁸ is selected from alkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl.

7. A compound of any of Claims 1-6 characterized in that J is -D-(CR¹⁴R^{14'})_tR¹⁵ and where t is 0; D is selected from -O-, -S-, SO₂, and -NR¹⁶- where R¹⁶ is selected from hydrogen, alkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; and R¹⁵ is selected from hydrogen, alkyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; or R¹⁶ joins with R¹⁵ to form a ring with 5 to 6 members of which 1 or 2 are heteroatoms.

8. A compound of any of Claims 1-7 characterized in that M is $-E-(CR^{19}R^{19'})_wR^{20}$ where w is 0 or 1; each R^{19} and $R^{19'}$ is hydrogen; E is selected from -O-, -S-, -SO₂- and NR²¹ where R²¹ is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; and R²⁰ is selected from hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl; or R²¹ joins with R²⁰ to form a 5 or 6 membered ring having 1 or 2 ring heteroatoms.
9. A compound of Claim 1 or Claim 8 characterized in that Q is $-G'-(CR^{22}R^{22'})_yR^{23}$ where y is 0; G' is selected from a covalent bond, -O- and -S-; and R²³ is selected from hydrogen and lower alkyl; or R²³ joins with R²⁰ to form a ring having 5 or 6 members with 1 or 2 ring heteroatoms.
10. A compound of Claim 1 characterized in that T is $-(CR^8R^{8'})_p-A-(CR^{8''}R^{8'''})_qR^9$ where p is 1; q is 0 or 1; each R⁸, R^{8'}, R^{8''}, and R^{8'''} is hydrogen; R⁹ is selected from hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl; and A is selected from a covalent bond, -O-, -S- and NR¹⁰ where R¹⁰ is selected from hydrogen, alkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl; or R¹⁰ joins with R⁹ to form an optionally substituted ring having 5 or 6 ring members of which 1 or 2 are heteroatoms.
11. A compound of any of Claims 1-10 characterized in that:
- (A) W is -CH=CH-;
 - (B) J is $-D-(CR^{14}R^{14'})_tR^{15}$ and where t is 0; D is selected from -O-, -S-, SO₂, and -NR¹⁶- where R¹⁶ is selected from hydrogen, alkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; and R¹⁵ is selected from hydrogen, alkyl, heteroalkyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; or R¹⁶ can join with R¹⁵ to form an optionally substituted ring with 5 to 6 members of 1 or 2 are heteroatoms;
 - (C) M is $-E-(CR^{19}R^{19'})_wR^{20}$ where w is 0 or 1; each R¹⁹ and R^{19'} is hydrogen; E is selected from -O-, -S-, -SO₂- and NR²¹ where R²¹ is selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; and R²⁰ is selected from hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; or R²¹ can join with R²⁰ to form an optionally substituted 5 or 6 membered ring having 1 or 2 ring heteroatoms.

12. A compound selected from the group consisting of:

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;

2-[(4'-(Methylthio)[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;

2-[(4'-Phenoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;

2-[(4'-(2-Methoxyethoxy)[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;

2-[(4'-(2-(1-Pyrrolidinyl)ethoxy)[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;

2-[(1,1':4',1''-Terphenyl)-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;

2-[(3',4'-(Methylenedioxy)[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;

2-[(3'-Ethoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;

2-[[4-[(4-Methoxyphenyl)ethynyl]phenyl]sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;

2-[[4-[(4-Methylphenyl)ethynyl]phenyl]sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;

2-[[4-(Phenylazo)phenyl]sulfonyl]amino-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;

2-[(4'-Chloro[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-thiazolylthio]-pentanoic acid;

2-[(4'-Bromo[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-thiazolylthio]-pentanoic acid;

2-[(4'-Trifluoromethyl[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-thiazolylthio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-(phenylthio)-pentanoic acid;

2-[[[1,1'-biphenyl]-4-yl]sulfonyl]amino-4-hydroxy-5-(phenylthio)-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-(benzylthio)-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(benzyl)sulfonyl]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-(phenylamino)-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(1H-1,2,4-triazol-3-yl)thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-(phenylamino)-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-imidazolyl)thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[[2-(5-methylbenzimidazolyl)]thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(4(3H)-quinazolinonyl)thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(6-ethoxy-2-benzothiazolyl)thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-benzothiazolylthio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-benzoxazolylthio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-benzimidazolylthio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-(1-methyl-1H-imidazol-2-yl)thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(1-methyl-1H-tetrazol-5-yl)thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(4-methyl-4(H)-1,2,4-triazol-3-yl)thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(5-(methylthio)-1,3,4-thiadiazol-2-yl)thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[2-thienylthio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(5-phenyl-1,3,4-oxadiazol-2-yl)thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(1-(4-methoxyphenyl)-1H-tetrazol-1-yl)thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(6-chloro-2-benzoxazolyl)thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[[3-(methylthio)-1,2,4-thiadiazol-5-yl]thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[[5-(4-pyridinyl)-1,3,4-oxadiazol-2-yl]thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(5-methoxybenzothiazol-2-yl)thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(5-methoxybenzimidazol-2-yl)thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(5-phenyl-1H-1,2,4-triazol-3-yl)thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-methyl-3-furanyl)thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(4-methoxyphenyl)thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[pyrimidin-2-ylthio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[4,6-dimethylpyrimidin-2-ylthio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[pyridin-2-ylthio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[purin-2-ylthio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[4-methylcoumarin-7-ylthio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[[4-methoxyphenyl)methyl]thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[[4-fluorophenyl)methyl]thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[furfurylthio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(2-thienyl)methylthio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-phenoxy-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[pyridin-3-yloxy]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[pyrimidin-2-yloxy]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-4-methyl-5-[(1-N-methylimidazol-2-yl-thio)-methyl]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-3-phenylmethoxy-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;

2-[(4'-Thiomethoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-3-phenylmethoxy-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-3,4-dihydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-3,4-dihydroxy-5-[(4-methyl-4(H)-1,2,4-triazol-3-yl)thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-3,4-dihydroxy-5-[(4-methyl-4(H)-1,2,4-triazol-3-yl)thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-4-methyl-5-[(3-trifluoromethylpyridin-2-yl)-thiomethyl]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-4-hydroxy-5-[(3-trifluoromethyl)-2-pyridyl-thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]-N-methyl-amino-4-hydroxy-5-(phenylthio)-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-3-phenylmethoxy-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;

2-[(4'-Thiomethoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-3-phenylmethoxy-4-hydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-3,4-dihydroxy-5-[(2-thiazolyl)thio]-pentanoic acid;

2-[(4'-Methoxy[1,1'-biphenyl]-4-yl)sulfonyl]amino-3,4-dihydroxy-5-[(4-methyl-4(H)-1,2,4-triazol-3-yl)thio]-pentanoic acid;

2-[(4'-Methoxy-[1,1'-biphenyl]-4-yl)-sulfonyl]-amino-3-(2-phenoxyethyl-[1,3]dioxan-2-yl)-propionic acid;

2-[(4'-Bromo-[1,1'-biphenyl]-4-yl)-sulfonyl]-amino-3-(2-phenoxyethyl-[1,3]dioxan-2-yl)-propionic acid;

2-[(4'-Methoxy-[1,1'-biphenyl]-4-yl)-sulfonyl]-amino-3-(2-thiophenoxyethyl-[1,3]dioxan-2-yl)-propionic acid;

2-[(4'-Methoxy-[1,1'-biphenyl]-4-yl)-sulfonyl]-amino-3-[2-(2-oxo-azepan-1-ylmethyl)-[1,3]dioxan-2-yl]-propionic acid, and

2-[(4'-Methoxy-[1,1'-biphenyl]-4-yl)-sulfonyl]-amino-3-(2-phenoxyethyl-[1,3]dioxan-2-yl)-propionic acid.

13. A pharmaceutical composition comprising:

- (a) a safe and effective amount of a compound of any of Claims 1-12; and
- (b) a pharmaceutically-acceptable carrier.

14. The manufacture of a medicament containing a safe and effective amount of a compound of any of Claims 1-12, characterized in that the medicament is administered to a mammalian subject for the treatment of a disease associated with unwanted metalloprotease activity.

15. The manufacture of a medicament containing a safe and effective amount of a compound of any of Claims 1-12, characterized in that the medicament is administered to a mammalian subject for the treatment of a disease associated with unwanted metalloprotease activity, further characterized in that the disease is chosen from the group consisting of arthritis, cancer, cardiovascular disorders, skin disorders, ocular disorders, inflammation and gum disease.

16. The medicament according to Claim 15, characterized in that the disorder is (a) arthritis, and is chosen from the group consisting of osteoarthritis and rheumatoid arthritis; (b) cancer, and the treatment prevents or arrests tumor growth and metastasis; or (c) a cardiovascular disorder chosen from the group consisting of dilated cardiomyopathy, congestive heart failure, atherosclerosis, plaque rupture, reperfusion injury, ischemia, chronic obstructive pulmonary disease, angioplasty restenosis, and aortic aneurysm.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 September 2000 (08.09.2000)

PCT

(10) International Publication Number
WO 00/51993 A3

- (51) International Patent Classification⁷: C07D 277/36, C07C 311/19, C07D 249/12, A61K 31/41, 31/426, C07D 233/84, 235/28, 239/95, 277/74, A61K 31/428, C07D 263/58, 257/04, A61K 31/433, C07D 285/125, 333/34, 271/113, 413/04, 307/64, 239/38, 213/70, 487/04, 311/16, A61K 31/4402, 31/4406, 31/44, A61P 19/02, 35/04, 9/00, C07D 319/04, 339/08 // (C07D 487/04, 239:00, 235:00)
- (21) International Application Number: PCT/US00/05195
- (22) International Filing Date: 1 March 2000 (01.03.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/122,718 3 March 1999 (03.03.1999) US
- (71) Applicant: THE PROCTER & GAMBLE COMPANY [US/US]; One Procter & Gamble Plaza, Cincinnati, OH 45202 (US).
- (72) Inventors: CHENG, Menyan; 5860 Hazeltine Court, West Chester, OH 45069 (US). ALMSTEAD, Neil, Gregory; 6348 Trail Ridge Court, Loveland, OH 45140 (US). NATCHUS, Michael, George; 1096 Laurel Avenue, Glendale, OH 45246 (US). PIKUL, Stanislaw; 4640 Placepointe Drive, Mason, OH 45040 (US). DE, Biswanath; 11269 Cornell Woods Drive, Cincinnati, OH 45241 (US).
- (74) Agents: REED, T., David et al.; The Procter & Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45217-1087 (US).
- (81) Designated States (*national*): AE, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— With international search report.
- (88) Date of publication of the international search report:
21 December 2000
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DIHETERO-SUBSTITUTED METALLOPROTEASE INHIBITORS

(57) Abstract: Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the compounds have a structure according to formula (I): where J, M, Q, T, W, X, Z, R¹, R², R³, R⁴, R^{4'}, R⁵, R⁶, R^{6'}, R⁷, m, and n have the meanings described in the specification. This invention also includes optical isomers, diastereomers and enantiomers of the formula above, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. Also disclosed are pharmaceutical compositions comprising these compounds, and methods of treating or preventing metalloprotease-related maladies using the compounds or the pharmaceutical compositions.

WO 00/51993 A3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/05195

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C07D277/36	C07C311/19	C07D249/12	A61K31/41	A61K31/426
	C07D233/84	C07D235/28	C07D239/95	C07D277/74	A61K31/428
	C07D263/58	C07D257/04	A61K31/433	C07D285/125	C07D333/34

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D C07C A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 06340 A (PROCTER & GAMBLE) 11 February 1999 (1999-02-11) see whole document, especially the examples and formula I	1-16
A	WO 98 08822 A (PROCTER & GAMBLE) 5 March 1998 (1998-03-05) the whole document	1-16
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

15 September 2000

Date of mailing of the international search report

28.09.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Scruton-Evans, I

INTERNATIONAL SEARCH REPORT

Inte ional Application No
PCT/US 00/05195

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D271/113 C07D413/04 C07D307/64 C07D239/38 C07D213/70
C07D487/04 C07D311/16 A61K31/4402 A61K31/4406 A61K31/44
A61P19/02 A61P35/04 A61P9/00 C07D319/04 C07D339/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	DE B ET AL: "The next generation of MMP inhibitors: design and synthesis" ANN. N. Y. ACAD. SCI. (ANYAA9,00778923);1999; VOL.878 (INHIBITION OF MATRIX METALLOPROTEINASES); PP.40-60, XP000916382 Procter & Gamble Pharmaceuticals;Mason; 45040-8006; OH; USA (US) the whole document --- -/--	1-16

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

15 September 2000

Date of mailing of the international search report

28.09.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Scruton-Evans, I

INTERNATIONAL SEARCH REPORT

Inte ional Application No

PCT/US 00/05195

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 //(C07D487/04,239:00,235:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	CHENG M ET AL: "Design, Synthesis, and Biological Evaluation of Matrix Metalloproteinase Inhibitors Derived from a Modified Proline Scaffold" J. MED. CHEM. (JMCMAR,00222623);1999; VOL.42 (26); PP.5426-5436, XP000919157 Procter and Gamble Pharmaceuticals;Mason; 45040; OH; USA (US) the whole document	1-16



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *8* document member of the same patent family

Date of the actual completion of the international search

15 September 2000

Date of mailing of the international search report

28.09.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Scruton-Evans, I

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/05195

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 14-16 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 1-11 (partly)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box 1.2

Claims Nos.: 1-11 (partly)

Present claims 1-11 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds wherein W is CH=CH and X is OH, with J as OH or R15 and R13 together as a cyclic C(X)(X) derivative (as in examples 68-72) i.e. all of the examples and closely related homologous compounds.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l. Application No

PCT/US 00/05195

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9906340 A	11-02-1999	AU 8237698 A EP 1009737 A NO 20000464 A ZA 9806835 A	22-02-1999 21-06-2000 30-03-2000 01-02-1999
WO 9808822 A	05-03-1998	AU 3985897 A BR 9713186 A CN 1228771 A CZ 9900628 A EP 0927168 A NO 990838 A PL 331838 A SK 24999 A	19-03-1998 03-11-1999 15-09-1999 14-07-1999 07-07-1999 28-04-1999 02-08-1999 14-02-2000

